EISAI CO., LTD. AND CONSOLIDATED SUBSIDIARIES QUARTERLY FINANCIAL REPORT RELEASE

FOR IMMEDIATE RELEASE October 31, 2008

Eisai Co., Ltd. hereby announces consolidated financial results for the Second Quarter of the fiscal year ending March 31, 2009.

Eisai Co., Ltd. is listed on the First Section of the Tokyo Stock Exchange and the Osaka Securities Exchange.

∉ Representative of corporation: Haruo Naito

Director, President and CEO

Inquiries should be directed to: Akira Fujiyoshi

Vice President

Corporate Communications

4-6-10 Koishikawa, Bunkyo-ku Tokyo 112-8088, Japan Phone: 81-3-3817-5120

URL http://www.eisai.co.jp/index-e.html

Expected date of Quarterly Financial Report submission: November 10, 2008 Expected date of initial payment of dividend:

November 19, 2008

1. CONSOLIDATED QUARTERLY FINANCIAL RESULTS Six-month ended September 30, 2008

1) RESULTS OF OPERATIONS

Period	Net Sales	Percent Change	Operating Income	Percent Change	Ordinary Income	Percent Change
April 1, 2008- Sept. 30, 2008	¥398,828 mil.	-%	¥46,544 mil.	-%	¥43,610 mil.	-%
April 1, 2007- Sept. 30, 2007	¥362,817 mil.	13.6%	¥57,061 mil.	14.9%	¥59,560 mil.	15.1%

Period	Net Income	Percent Change	Basic Earnings per Share	Diluted Earnings per Share
April 1, 2008- Sept. 30, 2008	¥28,712 mil.	-%	¥100.78	¥100.74
April 1, 2007- Sept. 30, 2007	¥39,351 mil.	21.0%	¥138.49	¥138.34

Note: Percentage Increase (decrease) reflects changes in comparison with the corresponding period of the previous year.

2) FINANCIAL POSITION

Period End	Total Assets	Equity	Shareholders' Equity Ratio	Book-value per share
Sept. 30, 2008	¥1,156,499 mil.	¥464,871 mil.	39.8%	¥1,614.51
March. 31, 2007	¥1,123,939 mil.	¥453,791 mil.	39.9%	¥1,575.49

Reference: Shareholders' Equity = Equity - Minority interests - Stock acquisition rights:

As of September 30, 2008:

459,991 million yen

• As of March 31, 2008:

448,860 million yen

2. DIVIDEND CONDITION

(Record Date)

Dividend per share
Second quarter Third quarter
end end end

4. OTHER

[Qualitative Information / Financial Statements]

Index and money amount comparisons to the previous period's figures are stated for reference in this

Consequently, net income per share on adjusted basis came to ¥141.32 (up ¥2.82 year-on-year).

[Cash generating ability]

Cash income* is the total amount of cash available for investment in future growth, business development, dividend payment and repayment of borrowings and it represents the company's ability to generate cash. In this financial reporting, cash income is stated as a measure to examine the company's growth potential and strategies.

Cash income for the period was ¥58,295 million (up 5.3% year on year).

*Cash income = Net income (loss) + depreciation of PP&E and amortization of intangible assets + in-process R&D expenses + amortization of goodwill + impairment loss on long-term assets

[Performance by segment]

(Sales for each segment are those to external customers.)

- (1) Performance by operating segment
- <Pharmaceuticals segment>
- **Sales of pharmaceuticals** increased as a result of the continued sales growth of *Aricept* as well as the contribution of MGI PHARMA's two main products.
- Pharmaceutical sales increased 10.5% year-on-year to ¥388,450 million, while operating income decreased 17.7% year-on-year to ¥47,920 million, due to the amortization of goodwill associated with the acquisition of MGI PHARMA, INC., which was completed in the previous period, and proactive investment in R&D activities.

<Other>

- Sales of food additives, chemicals and machinery decreased 8.7% year-on-year to ¥10,378 million, and operating income also decreased 14.4% year-on-year to ¥846 million.
- (2) Performance by geogr BT/TT0 1 Tfij-3 Tw 13..pi4/005 geo4627n>>BDC 12 Tw T*Asil82ls t À

the previous year.

"HUMIRA subcutaneous injection 40mg Syringe 0.8mL,"

2) Second Quarter Financial Highlights (July 1- September 30, 2008)

- Consolidated net sales during the quarter amounted to ¥203,008 million, an increase of 8.7% from the previous year.
- Net sales of *Aricept* came to ¥79,639 million, an 8.3% rise year-on-year, out of which ¥18,811 million was attributed to Japan, up 24.5%, and ¥49,850 million was attributed to the U.S., up 3.8% (14.1% rise on a U.S. dollar-denominated basis).

Sales of *Pariet/Aciphex* totaled ¥41,710 million, an 11.9% decrease year-on-year, out of which ¥10,638 million was attributed to Japan, up 14.1%, and ¥26,970 million was attributed to the U.S., down 22.0% (14.5% decrease on a U.S. dollar-denominated basis).

Sales of *Aloxi* **were ¥9,466 million and sales of** *Dacogen* **came to ¥4,305 million.**

- With respect to sales to external customers in each geographic area, sales in Japan increased 3.4%, while those in the North America, Europe, China, and "Asia and other (excluding China)" expanded by 12.0%, 14.7%, 32.5% and 7.5%, respectively.
- **R&D expenses** came to ¥42,303 million, up 26.9% from the previous period, and **Selling, general and administrative expenses** amounted to ¥98,354 million, up 3.0%. **Cost of goods sold** went up 47.2%, to ¥39,867 million, and the cost of sales ratio increased by 5.1 percentage points, to 19.6%.
- Operating income was ¥22,483 million, down 27.2% year-on-year, ordinary income was ¥19,747 million, down 36.7%, and net income was ¥12,076 million, down 39.7%. Net income per share decreased by ¥28.04 to ¥42.39. Operating income, ordinary income and net income on an adjusted basis were ¥29,789 million (down 3.5% year-on-year), ¥27,052 million (down 13.3%) and ¥17,638 million (down 11.9%), respectively, while net income per share on an adjusted basis was ¥61.91 (down ¥8.52).
- Net cash provided by operating activities came to ¥50,772 million, up ¥16,863 million year-on-year. Income before income taxes amounted to ¥18,430 million, depreciation and amortization expenses were ¥12,631 million, trade receivables increased by ¥9,041 million, while income taxes paid totaled ¥1,562 million.

Net cash used in investing activities increased ¥2,605 million to ¥9,273 million, out of which ¥8,356 million was used to purchase property, plant and equipment.

Net cash used in financing activities amounted to ¥5,538 million, an increase of ¥5,463 million from the same period of the previous year.

3) Research & Development and Other Events Status of Ongoing Research Projects

- Anticancer agent E7389 (microtubule dynamics inhibitor) is being investigated for a breast cancer indication in a Phase III study in the U.S. and in Europe, and in a Phase II study in Japan. Phase II studies are ongoing for non-small cell lung cancer (the U.S.), prostate cancer (the U.S. and Europe), and sarcoma (Europe).
- An AMPA receptor antagonist E2007 is being investigated with a focus on neuropathic pain and epilepsy indications. In the U.S. and Europe, a Phase III study for epilepsy has been initiated, and a Phase II study is ongoing for neuropathic pain.
- An endotoxin antagonist E5564 is being investigated in a Phase III study for the potential treatment of severe sepsis in Japan, the U.S. and Europe with a plan to submit applications simultaneously at these locations. The study is being conducted at multiple sites globally.
- A new oral formulation of an anti-emetic agent *Aloxi* (capsules) received approved for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) in the U.S. in August 2008.
- In October 2008, the U.S. FDA approved an efficacy supplemental biologics license application (sBLA) for *Ontak* solution for intravenous injection for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the interleukin (IL)-2 receptor (CD25+). The FDA's action, following a priority review, marks the conversion of an accelerated approval indication to full approval. A separate sBLA, which was submitted for the potential treatment of patients with CTCL whose malignant cells did not test positive for the CD25 component of the IL-2 receptor, received a complete response letter and was not approved. Eisai will continue to work with FDA to seek the approval.
- A submission is in preparation for the DNA hypomethylating agent **Dacogen** for a five day dosing regimen for the treatment of myelodysplastic syndromes (MDS) in the U.S.
- The development of **the anti-epileptic drug** Zonegran was determined to focus on monotherapy in epilepsy and adjunctive therapy in pediatric epilepsy, both of which are being investigated in Phase III studies in Europe. Accordingly, the study for an indication of generalized seizures (adjunctive

- therapy) in Europe was terminated.
- A Phase II study of **anticancer agent E7080** (VEGF receptor tyrosine kinase inhibitor) in the U.S. for the indication of thyroid cancer.
- Human monoclonal anti-TNF antibody HUMIRA was approved for the treatment of rheumatoid arthritis in Japan in April 2008.
- Non-ionic contrast media *lomeron* 350 and *lomeron* 350 syringe received additional approval for usage in dynamic computed tomography of the liver (dynamic CT) in Japan in May 2008. In addition, a higher volume of lomeron 350 syringe (135 ml formulation) was approved.
- A Phase III study of **SEP-190 (GABA_A receptor agonist)** has been initiated for insomnia indication in Japan.
- A gastroprokinetic agent *Gasmotin* received approval for the treatment of gastrointestinal symptoms associated wit

Alliances & Agreements

- Agreements were concluded with Eisai's diagnostic subsidiary Sanko Junyaku Co., Ltd., Roche Diagnostics K.K., Nihon Kohden Corporation, and F. Hoffmann-La Roche Ltd (Switzerland) in April 2008 concerning the sale of CoaguChek XS and CoaguChek XS Plus for simple and quick PT-INR (Prothrombin Time International Normalized Ratio) monitoring along with other related supplies. Under these agreements, effective June 2008, the sales rights of these products in Japan have been transferred from Roche Diagnostics and Nihon Kohden to Sanko Junyaku, with co-promotion rights retained by Eisai. Roche Diagnostics remains as a manufacturer (importer) of CoaguChek XS Series, and Nihon Kohden offers sales and technical support as the distributor.
- Lion Corporation and Eisai Co., Ltd. signed an agreement granting Eisai exclusive marketing rights in Japan for the Bufferin (ethical drug) in May, 2008. Prior to this action, Lion Corporation, Bristol-Myers K. K. (BMKK) and Eisai Co., Ltd. had agreed to change the distributor of Bufferin 81mg Tablets (antiplatelet drug), and Bufferin 330mg Tablets (antipyretic /analgesic/ antiphlogistic drug) from BMKK to Eisai starting July 1, 2008. The manufacturing and marketing rights of these products in Japan are owned by Lion.
- GlaxoSmithKline K.K. and Eisai Co., Ltd. agreed to terminate their marketing alliance for the *Breathe Right*, nasal strips manufactured by GlaxoSmithKline group, effective May 31, 2008. The product had been marketed in Japan by Eisai. As a result, the GlaxoSmithKline K.K. has taken over the marketing of the product in Japan as of June 1, 2008.
- Eisai Co., Ltd. entered into a share transfer agreement with Terumo Corporation for the transfer of Eisai's interest (84.8% of total shares issued) in its consolidated subsidiary, Clinical Supply Co., Ltd., to Terumo Corporation in June 2008. The shares were transferred in June 2008 following the execution of this agreement.
- Eisai's U.S. subsidiary Morphotek, Inc. signed a license agreement with the National Cancer Institute (NCI) for the rights to a monoclonal antibody for a novel antigen identified by NCI researchers in June 2008. Morphotek will apply its proprietary MORPHODOMA antibody technology to the development of novel human therapeutic antibodies for use in the treatment of prostate cancer.

- Eisai's subsidiary Eisai China Inc. entered into a license agreement in July 2008 with Hong-Kong-based Health Vision Enterprise Ltd., a sales subsidiary of the German company STADA Arzneimittel AG, in which Eisai China Inc. was granted rights in China to sell and repackage of α -Lipon 300 STADA (generic name: α -lipoic acid). α -Lipon 300 STADA is a treatment for diabetic neuropathic pain developed by STADA.
- Morphotek, Inc. and Pivotal BioSciences, Inc. (the U.S.) entered into an agreement in which Morphotek will access Pivotal BioSciences' LEC (Liver-Expression Chemokine) platform technology for the development of therapeutic monoclonal antibodies in July 2008. The agreement will allow Morphotek to evaluate the LEC technology in-house and give the company the right to exercise an option for a license. Should Morphotek choose to exercise its option, Morphotek woul

2. Consolidated Financial Position

[Assets, liabilities and equity]

Total assets at the end of the period increased by ¥32,560 million year-on-year to ¥1,156,499 million. Higher balances of short-term investments, property, plant and equipment, and deferred tax assets contributed to the increase. Invest

- receivables increased to ¥8,788 million, and income taxes paid totaled ¥17,025 million.
- Net cash used in investing activities amounted to ¥17,009 million, a decrease of ¥35,615 million, out of which ¥19,903 million was used to purchase property, plant and equipment.
- Net cash used in financing activities amounted to ¥25,542 million, an increase of ¥6,766 million from the same period of the previous year, out of which ¥18,518 million was paid as dividends. Short-term loan borrowed for the acquisition has been refinanced with straight bonds and long-term borrowings.
- As a result of such operating, investing and financing activities, **cash and cash equivalents** at the end of the period came to ¥142,088 million, up ¥22,138 million from the end of the previous period.

3. Basic policy on profit appropriation and dividend for the end of second quarter for the fiscal year ending March 31, 2009

Eisai is a company with a committee system and, to facilitate a flexible dividend policy, as specified in the Company's Articles of Incorporation, dividend payments are to be determined by a resolution of the Board of Directors.

Eisai is devoted to providing sustainable and stable dividends based on the consolidated financial performance along with the Dividend on Equity ratio (DOE). DOE is considered a suitable and well-balanced index for shareholder return as it encompasses both the Dividend Payout Ratio (DPR), which measures the extent to which profits are distributed to shareholders in the form of dividends, and Return on Equity (ROE), which measures how effectively the company uses the money invested by shareholders to generate profits.

Based on the company's dividend policy and increased cash income per share, Eisai intends to set the interim dividend at ¥70 per share (an increase of ¥5 from the previous year).

Acquisition of treasury stock will be carried out flexibly on a timely basis.

4. Outlook for the Fiscal Year Ending March 31, 2009

[Consolidated Forecast]

The full-year consolidated forecast announced in July 2008 has been revised as follows:

Revised Forecast		Forecast in July '08		Increase/ (Decrease)	Rate of
(A)	y/y (%)	(B)	y/y (%)	(A-B)	Changes

- which will result in decrease in expenses related to the acquisition of MGI PHARMA, INC.
- GAAP-based ordinary income is declined by ¥500 million from the previous forecast to ¥86,500 million, and net income is increased by ¥500 million to ¥56,500 million.
- We also envision a proactive investment in R&D activities and for future growth on a continuous basis, while taking effort to achieve improvement in cost-to-sales ratio and efficiency in managerial resources

[Projected year-end dividend]

- ' Projected year-end dividend remains unchanged.
- Year-end dividend is anticipated to be ¥70 per share (an increase of ¥5 per share from the previous year), which, together with the interim dividend of ¥70 per share, makes a total of ¥140 per share (an increase of ¥10 per share from the previous year). In this context, DOE is anticipated to be 8.9%.

(Reference)

[Non-consolidated Forecast]

The full-year non-consolidated forecast announced in May 2008 has been revised as follows:

	Revised Forecast		Forecast in Ju	Forecast in July '08		Rate of	
	(A)	y/y (%)	(B)	y/y (%)	(A-B)	Changes	
Net sales	¥405,000 mil.	+4.1	¥398,000 mil.	+2.3	¥7,000 mil.	1.8%	
Operating income	¥70,000 mil.	-4.2	¥66,500 mil.	-9.0	¥3,500 mil.	5.3%	
Ordinary	¥62,500 mil.	-12.0	¥59,500 mil.	-16.2	¥3,000 mil.	5.0%	
income							
Net income	¥46,500 mil.	+1.1	¥40,000 mil.	-13.0	¥6,500 mil.	16.3%	

Notes:

(Assumptions for the 3rd and 4th quarter) US\$1=¥100, 1 Euro =¥135, 1 Sterling Pound =¥175

^{*}Forecasted Annual Earnings per share (full year): ¥163.21

^{*}y/y : Percentatge compared with the previous year

- industry and market conditions, and domestic and international economic conditions, such as interest rate and currency exchange fluctuations.
- Risks that may cause significant fluctuations in the consolidated results of the Company or have a material effect on investment decisions of shareholders are described below. These are risk factors that have been identified and assessed as of the disclosure date of the Financial Report. Risk factors associated with our business include, but are not limited to, challenges arising out of global exp

5. Corporate Governance

Chair of the Board of Directors. The Committee agreed to propose a continuation of the Policy in its present form to the Board of Directors, with only a minor and cosmetic change in description caused by the shift of the subject law. The Board of Directors discussed and resolved to continue the Policy at its meeting held on July 31, 2008.

Eisai will continue to pursue fair and highly transparent operation through fulfillment of sound corporate governance policies, as well as active and appropriate information disclosure on a timely basis.

Detailed information on Eisai's corporate governance is available on the corporate website (http://www.eisai.co.jp/ecompany/egovernance.html) along with the Company's Corporate Governance guidelines, Rules of the Board of Directors, Rules of the Nominating Committee, Rules of the Audit Committee, and Rules of the Compensation Committee.

The Corporate Governance Report submitted to the Tokyo Stock Exchange (TSE) and Osaka Securities Exchange (OSE) is available on the websites of TSE, OSE and Eisai.

6. Other

- 1) Simplified accounting treatments and specific accounting treatment in the quarterly financial statements
- (1) Simplified accounting treatments
 - a) The balances of inventories as of September 30, 2008 are allowed to be calculated based on the physical counts

c) Effective from this fiscal year, the Company applied the new Practical Issues Task Force (PITF), "Practical Solution on Unification of Accounting Policies Applied to Foreign Subsidiaries for Consolidated Financial Statements (ASBJ PITF No. 18, May 17, 2006)," and accordingly made any necessary modifications including amortization of goodwill to its consolidated financial statements. The effect of adoption of this standard was to decrease operating income, and ordinary income and income before income taxes, and minority interests for the current six-month period by ¥4,953 million and ¥4,867 million, respectively. The effect of this change on segment information is stated in the relevant sections. Goodwill purchased by an overseas subsidiary is amortized over 20 years.

(2) Changes other than (1)

a) Previously, Eisai and its domestic subsidiaries had amortized their

expected to remain regular, with few severe fluctuations.

The effect of adoption of this change from the declining balance method to the straight line method on the results of the current six-month period was to decrease consolidated depreciation expenses by ¥1,207 million and increase operating income, ordinary income, and income before income tax and minority interests by ¥817 million, respectively.

With the start of the change of depreciation method, the Company and its subsidiaries have introduced a unified treatment on residual values in which depreciable assets are to be depreciated to 1 yen (the defined residual value) at the end of their useful life.

The effect of adoption of this change on the results of the current six-month period was to increase depreciation expenses by ¥1,012 million and decrease operating income, ordinary income, and income before income tax and minority interests by ¥668 million.

The aggregated effect of the change to the straight line method and the change in residual value as stated above on the results of the current six-month period was to decrease amortization costs by ¥195 million and increase operating income, ordinary income, and income before income tax and minority interests by ¥148 million, respectively. The effect of this change on segment information is stated in the relevant sections.

b) Effective from this fiscal year, Eisai has implemented early adoption of the "Accounting Standard for Lease Transactions (Statement No.13, amended

c). Significant Hedge accounting

The Company entered into interest rate swaps agreements during current second quarter as a means of managing its interest rate exposure on the parts of long-term borrowings. The accounting treatment of derivative financial Instruments under hedge accounting are as follows:

i) Hedging accounting method

All derivatives are recognized as either assets or liabilities and measured at fair value, and gains or losses on derivative transactions are recognized in the income statement, and for derivatives used for hedging purposes, if derivatives qualify for hedge accounting because of high correlation and effectiveness between the hedging instruments and the hedged items, gains or losses on derivatives are deferred until maturity of the hedged transactions.

The interest rate swaps which qualify for hedge accounting and meet specific matching criteria are not remeasured at market value but the differential paid or received under the swap agreements are recognized and included in interest expense or income.

ii) Hedging instruments and hedged itemsHedging instruments Interest rate swapsHedged itemsLong-term borrowings

iii) Hedging policies

The Company uses derivative financial instruments for long-term borrowings to manage their exposures to fluctuations in interest rates in accordance with internal policies which regulate the authorization and credit limit amount, and interest rate swaps are utilized by the Company to reduce interest rate risks.

iv) Method for evaluation of effectiveness of hedging instruments

The Company evaluates high correlation and effectiveness between the hedging instruments and the hedged items at every quarterly period end.

The Company is allowed to omit this evaluation for Interest rate swap which qualify for hedging accounting and meet specific matching criteria.

7. CONSOLIDATED FINANCIAL STATEMENTS

(millions of yen)

September 30, 2008

March 31, 2008

ASSETS

Current assets:

Cash and cash in banks 64,969 68,593

2) CONSOLIDATED STATEMENT OF INCOME Six months ended September 30, 2008

(millions of yen)

	April 1, 2008 - September 30, 2008
Net sales	398,828
Cost of sales	79,219
Gross profit on sales	319,609
Provision for sales returns-net	0
Gross profit	319,609
Selling, general and administrative expenses*	273,064
Operating income	46,544
Non-operating income	
Interest income	1,802
Dividend income	566
Amortization of negative goodwill	162
Other	191
Total non-operating income	2,722
Non-operating expenses	
Interest expenses	3,445
Bond issue costs	348
Foreign exchange loss	1,061
Equity in loss of an associated company	53
Other	747
Total non-operating expenses	5,656
Ordinary income	43,610
Special gain	
Gain on sales of fixed assets	10
Gain on sales of investment securities	432
Gain on sale of a consolidated subsidiary	1,575
Other	1
Total special gain	2,019
Special loss	
Loss on disposal of non-current assets	142
Loss on devaluation of investment securities	1,448
Retirement benefit costs	377
Other	53
Total special loss	2,022
Income before income taxes and minority interests	43,607
Income taxes-current	24,553
Income taxes-deferred	(9,980)
Total Income taxes	14,572
Minority interests in net income	322
Net income	28,712

July 1, 2008 - September 30, 2008

	July 1, 2008 - September 30, 2008
Net sales	203,008
Cost of sales	39,874
Gross profit on sales	163,134
Reversal of sales returns-net	6
Gross profit	163,141
Selling, general and administrative expenses*	140,657
Operating income	22,483
Non-operating income	
Interest income	1,002
Dividend income	20
Amortization of negative goodwill	81
Other	89
Total non-operating income	1,193
Non-operating expenses	
Interest expenses	1,930
Foreign exchange loss	1,301
Equity in loss of an associated company	45
Other	651
Total non-operating expenses	3,929
Ordinary income	19,747
Special gain	
Gain on sales of non-current assets	5
Other	1
Total special gain	7
Special loss	
Loss on disposal of fixed assets	83
Loss on devaluation of investment securities	837
Retirement benefit costs	377
Other	25
Total special loss	1,324
Income before income taxes and minority interests	18,430
Income taxes-current	8,512
Income taxes-deferred	(2,281)
Total Income taxes	6,231
Minority interests in net income	122
Net income	12,076

3) CONSOLIDATED STATEMENT OF CASH FLOWS Six months ended September 30, 2008

(millions of yen)

	April 1, 2008 - September 30, 2008
Operating activities:	
Income before income taxes and minority interests	43,607
Depreciation and amortization	24,900
Amortization of goodwill	4,845
Other loss (income)	2,333
Decrease (Increase) in notes and accounts receivable-trade	(8,788)
Decrease (Increase) in inventories	(1,645)
Increase (Decrease) in notes and accounts payable-trade	1,954
Increase (Decrease) in other current liabilities	12,507
Increase (Decrease) in reserve for sales rebates	5,692
Other-net	1,314
Sub-total	86,721
Interest and dividends received	2,282
Interest paid	(2,640)
Income taxes-paid	(17,025)
Net cash provided by operating activities	69,336
Investing activities:	
Purchases of property, plant and equipment	(19,903)
Purchases of intangible assets	(3,217)
Purchases of securities	(1,304)
Proceeds from sales and redemption of securities	6,210
Other-net	1,205
Net cash used in investing activities	(17,009)
Financing activities:	
Net increase (decrease) in short-term borrowings	(359,539)
Proceeds from long-term borrowings	233,812
Proceeds from bonds and debentures	119,616
Dividends paid	(18,518)
Other-net	(912)
Net cash used in financing activities	(25,542)
Foreign currency translation adjustments on cash and cash equivalents	(4,646)
Net increase (decrease) in cash and cash equivalents	22,138
Cash and cash equivalents at beginning of period	119,950
Cash and cash equivalents at end of period	142,088

4) Going ConcernNot applicable

5) Segment Information

(1) Business Segment Information

Three months ended September 30, 2008

(millions of yen)

Pharmaceuticals

(2) Geographical Segment Information

Three months ended September 30, 2008

(millions of yen)

Japan

(3) Overseas Sales

Three months ended September 30, 2008

					(millions of yen)
	North America	Europe	China	Asia and Others	Total
Overseas sales	100,989	18,779	3,265		

CONSOLIDATED STATEMENTS OF INCOME (for reference) Six months ended September 30, 2007

OIX MONING CHACA COPICINDE 30, 2007	April 1, 2007 - September 30, 2007	
Account Title		of yen)
I. Net sales		362,817
II. Cost of sales		54,694
Gross profit on sales		308,123
Provision for (Reversal) of sales returns-net		(104)
Gross profit		308,227
III. Selling, general and administrative expenses		
Research and development expenses	63,844	
Selling, general and administrative expenses	187,321	251,166
Operating income		57,061
IV. Non-operating income		
1. Interest income	2,705	
2. Dividend income	495	
3. Other	147	3,348
V. Non-operating expenses		
Interest expenses	57	
2. Foreign exchange loss	478	
3. Equity in loss	16	
4. Sales discount	126	
5. Other	169	848
Ordinary Income		59,560
VI. Special gain		
Gain on sales of non-current assets	44	
Gain on sales of investment securities	2,202	
3. Other	10	2,258
VII. Special loss		
Loss on disposal of fixed assets	243	
Loss on impairment of long-lived assets	1	
Loss on devaluation of work-in-process inventory	845	
4. Other	7	1,099
Income before income taxes and minority interests		60,719
Income taxes-current	25,350	
Income taxes-deferred	(4,391)	20,958
Minority interests in net income		409
Net income		39,351

CONSOLIDATED STATEMENT OF INCOME (for reference) Three months ended September 30, 2007

Account Title

I. Net sales		186,783
II. Cost of sales		27,092
Gross profit on sales		159,690
Provision for (Reversal of) sales returns-net		(6)
Gross profit		159,697
III. Selling, general and administrative expenses		
Research and development expenses	33,338	
2. Selling, general and administrative expenses	95,483	128,821
Operating income		30,875
IV. Non-operating income		996
V. Non-operating expenses		678
Ordinary income		31,193
VI. Special gain		40
VII. Special loss		1,064
Income before income taxes and minority interests		30,169
Income taxes-current	11,813	
Income taxes-deferred	(1,830)	9,982
Minority interests in net income		174
Net income		20,012

CONSOLIDATED STATEMENT OF CASH FLOWS (for reference) Six months ended September 30, 2007

Account Title (millions of yen) I. Operating activities: 1. Income before income taxes and minority interests 60,719 2. Depreciation and amortization 15,364 3. Loss on impairment of long-lived assets 11 4. Increase (Decrease) in allowance for doubtful accounts 17 5. Interest and dividend income (3,200) 6. Interest expenses 57 7. Equity in (earnings) loss 57 7. Equity in (earnings) loss 16 8. (Gain) Loss on sales and disposal of fixed assets 199 9. (Gain) Loss on sales and disposal of fixed assets 199 9. (Gain) Loss on sales and experiments 199 10. Loss on devaluation of securities (2,202) 10. Loss on devaluation of securities (4,515) 11. (Increase) Decrease in inventories (865) 13. Increase (Decrease) in notes and accounts receivables-trade (4,515) 13. Increase (Decrease) in other current liabilities (4,787) 14. Increase (Decrease) in notes and accounts payable-trade (2,211) 14. Increase (Decrease) in other current liabilities (3,644) 15. Increase (Decrease) in reserve for sales rebates (351) 16. Increase (Decrease) in interest referent benefits (3,694) 17. Other-net (1,081) 18. Interest and dividends received (3,141) 19. Interest paid (5,2) 20. Income taxes-paid (24,404) Net cash provided by operating activities (1,43) 11. Investing activities: (1,635) 12. Proceeds from sales and redemption of short-term investment (6,35) 15. Purchases of short-term investment (1,643) 16. Purchases of short-term investment (1,643) 17. Purchases of investment securities (1,643) 18. Interest and dividends received (3,645) 19. Purchases of short-term investment (4,643) 10. Purchases of investment securities (4,649) 10. Purchases of investment securities (4,649) 10. Other-net (4,649) 10. Alternative and cash equivalents at deginating of period (4,649) 11. Cash and cash equivalents at tend of period (4,649		April 1, 2007 -
I. Operating activities: 1. Income before income taxes and minority interests 2. Depreciation and amortization 3. Loss on impairment of long-lived assets 4. Increase (Decrease) in allowance for doubtful accounts 5. Interest and dividend income 6. (Gain) Loss on sales and disposal of fixed assets 7. Equity in (earnings) loss 8. (Gain) Loss on sales and disposal of fixed assets 9. (Gain) Loss on sales and sposal of fixed assets 19. (Gain) Loss on sales of securities 10. (Sacrease) Decrease in notes and accounts receivables-trade 11. (Increase) Decrease in notes and accounts receivables-trade 12. (Increase) Decrease in notes and accounts payable-trade 13. Increase (Decrease) in other current liabilities 14. Increase (Decrease) in other current liabilities 15. Increase (Decrease) in reserve for sales rebates 16. Increase (Decrease) in reserve for sales rebates 17. Other-net 18. Interest and dividends received 19. Interest paid 10. Loss on devaluation of securities 10. Increase (Decrease) in reserve for sales rebates 10. Increase (Decrease) in liability for retirement benefits 10. Increase (Decrease) in		September 30, 2007
1. Income before income taxes and minority interests 60,719 2. Depreciation and amortization 15,364 3. Loss on impairment of long-lived assets 1 4. Increase (Decrease) in allowance for doubtful accounts 17 5. Interest and dividend income (3,200) 6. Interest expenses 57 7. Equity in (earnings) loss 16 8. (Gain) Loss on sales and disposal of fixed assets 19 9. (Gain) Loss on sales and disposal of fixed assets 19 9. (Gain) Loss on sales of securities (2,202) 10. Loss on devaluation of securities 5 11. (Increase) Decrease in inventories (865) 12. (Increase) Decrease in inventories (865) 13. Increase (Decrease) in notes and accounts payable-trade (2,211) 14. Increase (Decrease) in insterent instellibilities 4,787 15. Increase (Decrease) in liability for retirement benefits (369) 17. Other-net (1,081) 18. Interest and dividends received 3,141 19. Interest paid (52,04) 20. Income taxes-paid (24,04) Net cash provided by operating activities <td< td=""><td>Account Title</td><td>(millions of yen)</td></td<>	Account Title	(millions of yen)
2. Depreciation and amortization 15,364 3. Loss on impairment of long-lived assets 17 4. Increase (Decrease) in allowance for doubtful accounts 17 5. Interest and dividend income (3,200) 6. Interest expenses 57 7. Equity in (learnings) loss 16 8. (Gain) Loss on sales and disposal of fixed assets 199 9. (Gain) Loss on sales of securities (2,202) 10. Loss on devaluation of securities 5 11. (Increase) Decrease in inventories (855) 13. Increase (Decrease) becrease in inventories (855) 13. Increase (Decrease) in notes and accounts payable-trade (2,211) 14. Increase (Decrease) in rotes and accounts payable-trade (2,211) 15. Increase (Decrease) in reserve for sales rebates (351) 16. Increase (Decrease) in reserve for sales rebates (351) 17. Other-net (1,081) Sub-total 63,045 18. Interest and dividends received 3,141 19. Interest paid (52) 20. Income taxes-paid (24,404) Net cash provided by operating activities (52) 1. Purchases of short-term investment (635)	I. Operating activities:	
3. Loss on impairment of long-lived assets 1 4. Increase (Decrease) in allowance for doubtful accounts 17 5. Interest and dividend income (3,200) 6. Interest expenses 57 7. Equity in (earnings) loss 16 6. (Gain) Loss on sales of securities (2,202) 10. Loss on devaluation of securities (2,202) 11. (Increase) Decrease in notes and accounts receivables-trade (4,515) 12. (Increase) Decrease in inventories (865) 13. Increase (Decrease) in notes and accounts payable-trade (2,211) 14. Increase (Decrease) in rother current liabilities 4,787 15. Increase (Decrease) in rother current liabilities (351) 16. Increase (Decrease) in reserve for sales rebates (351) 17. Other-net (1,081) 18. Interest and dividends received 3,141 19. Interest and dividends received 3,141 19. Interest paid (52) 20. Income taxes-paid (24,404) Net cash provided by operating activities 41,730 11. Investing activities: (635) 12. Proceeds from sales and redemption of short-term investments (635) 2. Proceeds from	Income before income taxes and minority interests	60,719
4. Increase (Decrease) in allowance for doubtful accounts 17 5. Interest and dividend income (3,200) 6. Interest expenses 57 7. Equity in (earnings) loss 16 8. (Gain) Loss on sales and disposal of fixed assets 199 9. (Gain) Loss on sales and securities 5 10. Loss on devaluation of securities 5 11. (Increase) Decrease in inventories (865) 13. Increase (Decrease in inventories (865) 13. Increase (Decrease) in other current liabilities 4,787 15. Increase (Decrease) in reserve for sales rebates (351) 16. Increase (Decrease) in liability for retirement benefits (354) 17. Other-net (1,081) Sub-total (52) 19. Interest paid (52) 20. Income taxes-paid (24,404) Net cash provided by operating activities 1,730 II. Investing activities: 1,635 1. Purchases of property, plant and equipment (635) 2. Proceeds from sales and redemption of short-term investments (4,543) 3. Purchases of intragible assets (7,558) 6. Purchases of intragible assets (7,558)	2. Depreciation and amortization	15,364
5. Interest and dividend income (3,200) 6. Interest expenses 57 7. Equity in (earnings) loss 16 8. (Gain) Loss on sales and disposal of fixed assets 199 9. (Gain) Loss on sales of securities (2,202) 10. Loss on devaluation of securities 5 11. (Increase) Decrease in notes and accounts receivables-trade (4,515) 12. (Increase) Decrease) in otes and accounts payable-trade (2,211) 14. Increase (Decrease) in other current liabilities 4,787 15. Increase (Decrease) in reserve for sales rebates (351) 16. Increase (Decrease) in liability for retirement benefits (3,894) 17. Other-net (3,084) 18. Interest and dividends received 3,141 19. Interest paid (52) 20. Income taxes-paid (52) 20. Income taxes-paid (52) 10. Income taxes-paid (52) 20. Income taxes posid (52) 11. Inversing activities: (635) 1. Purchases of short-term investment (635) 2. Proceeds from sales and redemption of short-term investments 1,453 3. Purchases of investment securities (12,204)	3. Loss on impairment of long-lived assets	1
6. Interest expenses 57 7. Equity in (earnings) loss 16 8. (Gain) Loss on sales and disposal of fixed assets 199 9. (Gain) Loss on sales of securities (2,202) 10. Loss on devaluation of securities 5 11. (Increase) Decrease in notes and accounts receivables-trade (4,515) 12. (Increase) Decrease in inventories (865) 13. Increase (Decrease) in othes and accounts payable-trade (2,211) 14. Increase (Decrease) in interest or sales rebates (351) 15. Increase (Decrease) in inserver for sales rebates (351) 16. Increase (Decrease) in liability for retirement benefits (3,694) 17. Other-net (1,081) Sub-total 63,045 18. Interest and dividends received 3,141 19. Interest paid (52) 20. Income taxes-paid (24,404) Net cash provided by operating activities 41,730 II. Investing activities: 1,63 2. Proceeds from sales and redemption of short-term investments (635) 3. Purchases of property, plant and equipment (16,443) 4. Proceeds from sales and redemption of short-term investments (7,558) 5.	4. Increase (Decrease) in allowance for doubtful accounts	17
7. Equity in (earnings) loss 16 8. (Gain) Loss on sales and disposal of fixed assets 199 9. (Gain) Loss on sales of securities (2,202) 10. Loss on devaluation of securities 5 11. (Increase) Decrease in notes and accounts receivables-trade (4,515) 12. (Increase) Decrease in notes and accounts payable-trade (2,211) 13. Increase (Decrease) in nother current liabilities 4,787 15. Increase (Decrease) in eserve for sales rebates (351) 16. Increase (Decrease) in liability for retirement benefits (3,694) 17. Other-net (1,081) 18. Interest and dividends received 3,141 19. Interest paid (52) 20. Income taxes-paid (24,404) Net cash provided by operating activities 41,730 II. Investing activities: (635) 19. Proceeds from sales and redemption of short-term investments 1,453 2. Proceeds from sales and redemption of short-term investments 1,643 4. Proceeds from sales of property, plant and equipment (16,443) 5. Purchases of intrangible assets (7,558) 6. Purchases of investment securities 10,615 7. Proceeds from sales and redemptions o	5. Interest and dividend income	(3,200)
8. (Gain) Loss on sales and disposal of fixed assets 199 9. (Gain) Loss on sales of securities (2,202) 10. Loss on devaluation of securities 5 11. (Increase) Decrease in notes and accounts receivables-trade (4,515) 12. (Increase) Decrease in inventories (865) 13. Increase (Decrease) in other current liabilities 4,787 15. Increase (Decrease) in reserve for sales rebates (351) 16. Increase (Decrease) in liability for retirement benefits (3,694) 17. Other-net (1,081) Sub-total 63,045 18. Interest and dividends received 3,141 19. Income taxes-paid (52) 20. Income taxes-paid (24,404) Net cash provided by operating activities (635) 1. Investing activities: (635) 2. Proceeds from sales and redemption of short-term investments 1,453 3. Purchases of short-term investment (635) 4. Proceeds from sales and redemption of short-term investments 1,464 5. Purchases of intangible assets (7,558) 6. Purchases of investment securities (12) 7. Proceeds from sales and redemptions of investment securities (39,166) <td>6. Interest expenses</td> <td>57</td>	6. Interest expenses	57
9. (Gain) Loss on sales of securities (2,202) 10. Loss on devaluation of securities 5 11. (Increase) Decrease in notes and accounts receivables-trade (4,515) 12. (Increase) Decrease in inventories (865) 13. Increase (Decrease) in notes and accounts payable-trade (2,211) 14. Increase (Decrease) in other current liabilities 4,787 15. Increase (Decrease) in reserve for sales rebates (351) 16. Increase (Decrease) in liability for retirement benefits (3,694) 17. Other-net (1,081) Sub-total 63,045 18. Interest and dividends received 3,141 19. Interest paid (52) 20. Income taxes-paid (24,404) Net cash provided by operating activities 41,730 11. Investing activities: (635) 12. Proceeds from sales and redemption of short-term investments (635) 2. Proceeds from sales and redemption of short-term investments (1,6443) 3. Purchases of intrangible assets (7,558) 4. Proceeds from sales and redemptions of investment securities (10,20) 5. Purchases of investment securities (12)	7. Equity in (earnings) loss	16
10. Loss on devaluation of securities 5 11. (Increase) Decrease in notes and accounts receivables-trade (4,515) 12. (Increase) Decrease in inventories (865) 13. Increase (Decrease) in notes and accounts payable-trade (2,211) 14. Increase (Decrease) in other current liabilities 4,787 15. Increase (Decrease) in reserve for sales rebates (351) 16. Increase (Decrease) in liability for retirement benefits (3,694) 17. Other-net (1,081) Sub-total 63,045 18. Interest and dividends received 3,141 19. Interest paid (52) 20. Income taxes-paid (24,404) Net cash provided by operating activities 41,730 II. Investing activities: (635) 1. Purchases of short-term investment (635) 2. Proceeds from sales and redemption of short-term investments 1,453 3. Purchases of investment securities (16,443) 4. Proceeds from sales of property, plant and equipment (16,443) 5. Purchases of investment securities (7,558) 6. Purchases of investment securities (12) 7. Proceeds from sal	8. (Gain) Loss on sales and disposal of fixed assets	199
11. (Increase) Decrease in notes and accounts receivables-trade (4,515) 12. (Increase) Decrease) in inventories (865) 13. Increase (Decrease) in other current liabilities (2,211) 14. Increase (Decrease) in other current liabilities 4,787 15. Increase (Decrease) in reserve for sales rebates (351) 16. Increase (Decrease) in liability for retirement benefits (3,894) 17. Other-net (1,081) Sub-total 63,045 18. Interest and dividends received 3,141 19. Interest paid (52) 20. Income taxes-paid (52) Net cash provided by operating activities 41,730 II. Investing activities: (835) 1. Purchases of short-term investment (635) 2. Proceeds from sales and redemption of short-term investments 1,453 3. Purchases of property, plant and equipment (16,443) 4. Proceeds from sales and redemptions of investment securities (7,558) 6. Purchases of intangible assets (7,558) 7. Proceeds from sales and redemptions of investment securities (39,166) 9. Net (increase) decrease in time deposits (exceeding 3 months) (35) 10. Other-net (2	9. (Gain) Loss on sales of securities	(2,202)
12. (Increase) Decrease in inventories (865) 13. Increase (Decrease) in notes and accounts payable-trade (2,211) 14. Increase (Decrease) in reserve for sales rebates (351) 16. Increase (Decrease) in liability for retirement benefits (3694) 17. Other-net (1,081) Sub-total 63,045 18. Interest and dividends received 3,141 19. Interest paid (52) 20. Income taxes-paid (24,404) Net cash provided by operating activities 41,730 II. Investing activities: (635) 1. Purchases of short-term investment (635) 2. Proceeds from sales and redemption of short-term investments 1,453 3. Purchases of property, plant and equipment (16,443) 4. Proceeds from sales of property, plant and equipment 102 5. Purchases of investment securities (12) 7. Proceeds from sales and redemptions of investment securities (12) 8. Payment for acquisition of business (39,166) 9. Net (increase) decrease in time deposits (exceeding 3 months) (35) 10. Other-net (943) Net increase (decrease) in short-term borrowings (245)	10. Loss on devaluation of securities	5
13. Increase (Decrease) in notes and accounts payable-trade (2,211) 14. Increase (Decrease) in other current liabilities 4,787 15. Increase (Decrease) in reserve for sales rebates (351) 16. Increase (Decrease) in liability for retirement benefits (3,694) 17. Other-net (1,081) Sub-total 63,045 18. Interest and dividends received 3,141 19. Interest paid (52) 20. Income taxes-paid (24,404) Net cash provided by operating activities 41,730 II. Investing activities: (635) 1. Purchases of short-term investment (635) 2. Proceeds from sales and redemption of short-term investments 1,453 3. Purchases of property, plant and equipment 102 5. Purchases of property, plant and equipment 102 6. Purchases of investment securities (7,558) 6. Purchases of investment securities (12) 7. Proceeds from sales and redemptions of investment securities (39,166) 9. Net (increase) decrease in time deposits (exceeding 3 months) (35) 10. Other-net (943) Net cash used in investing	11. (Increase) Decrease in notes and accounts receivables-trade	(4,515)
13. Increase (Decrease) in notes and accounts payable-trade (2,211) 14. Increase (Decrease) in reserve for sales rebates (351) 15. Increase (Decrease) in reserve for sales rebates (358) 16. Increase (Decrease) in liability for retirement benefits (3,694) 17. Other-net (1,081) Sub-total 63,045 18. Interest and dividends received 3,141 19. Interest paid (52) 20. Income taxes-paid (24,404) Net cash provided by operating activities 41,730 II. Investing activities: 1 1. Purchases of short-term investment (635) 2. Proceeds from sales and redemption of short-term investments 1,453 3. Purchases of property, plant and equipment 102 5. Purchases of investment securities (7,558) 6. Purchases of investment securities (12) 7. Proceeds from sales and redemptions of investment securities (39,166) 9. Net (increase) decrease in time deposits (exceeding 3 months) (35) 10. Other-net (943) Net cash used in investing activities (245) 11. Financing activities: (245) 2. Dividends paid	12. (Increase) Decrease in inventories	(865)
14. Increase (Decrease) in other current liabilities 4,787 15. Increase (Decrease) in reserve for sales rebates (351) 16. Increase (Decrease) in liability for retirement benefits (3,694) 17. Other-net (1,081) Sub-total 63,045 18. Interest and dividends received 3,141 19. Interest paid (52) 20. Income taxes-paid (24,404) Net cash provided by operating activities 41,730 II. Investing activities: (635) 1. Purchases of short-term investment (635) 2. Proceeds from sales and redemption of short-term investments 1,453 3. Purchases of property, plant and equipment 102 5. Purchases of intengible assets (7,558) 6. Purchases of investment securities (12) 7. Proceeds from sales and redemptions of investment securities 10,615 8. Payment for acquisition of business (39,166) 9. Net (increase) decrease in time deposits (exceeding 3 months) (35) 10. Other-net (943) Net cash used in investing activities (52,625) III. Financing activities: (245) 2. Dividends paid (18,468) <td>13. Increase (Decrease) in notes and accounts payable-trade</td> <td></td>	13. Increase (Decrease) in notes and accounts payable-trade	
15. Increase (Decrease) in reserve for sales rebates (351) 16. Increase (Decrease) in liability for retirement benefits (3,694) 17. Other-net (1,081) Sub-total 63,045 18. Interest and dividends received 3,141 19. Interest paid (52) 20. Income taxes-paid (24,404) Net cash provided by operating activities 41,730 II. Investing activities: *** 1. Purchases of short-term investment (635) 2. Proceeds from sales and redemption of short-term investments 1,453 3. Purchases of property, plant and equipment (16,443) 4. Proceeds from sales of property, plant and equipment 102 5. Purchases of intangible assets (7,558) 6. Purchases of investment securities (12) 7. Proceeds from sales and redemptions of investment securities (39,166) 8. Payment for acquisition of business (39,166) 9. Net (increase) decrease in time deposits (exceeding 3 months) (35) 10. Other-net (943) Net cash used in investing activities (245) 11. Financing activities: (245) 12. Dividends paid (18,468)<	· · · · · · · · · · · · · · · · · · ·	
16. Increase (Decrease) in liability for retirement benefits (3,694) 17. Other-net (1,081) Sub-total 63,045 18. Interest and dividends received 3,141 19. Interest paid (24,404) Net cash provided by operating activities 41,730 II. Investing activities: (635) 1. Purchases of short-term investment (635) 2. Proceeds from sales and redemption of short-term investments 1,453 3. Purchases of property, plant and equipment (16,443) 4. Proceeds from sales of property, plant and equipment 102 5. Purchases of investment securities (7,558) 6. Purchases of investment securities (12) 7. Proceeds from sales and redemptions of investment securities 10,615 8. Payment for acquisition of business (39,166) 9. Net (increase) decrease in time deposits (exceeding 3 months) (35) 10. Other-net (943) Net cash used in investing activities (245) II. Financing activities: (245) I. Net increase (decrease) in short-term borrowings (245) 2. Dividends paid (18,468) 3. Dividends paid to minority shareholde	· · · · · · · · · · · · · · · · · · ·	(351)
17. Other-net (1,081) Sub-total 63,045 18. Interest and dividends received 3,141 19. Interest paid (52) 20. Income taxes-paid (24,404) Net cash provided by operating activities 41,730 II. Investing activities: (635) 1. Purchases of short-term investment (635) 2. Proceeds from sales and redemption of short-term investments 1,453 3. Purchases of property, plant and equipment (16,443) 4. Proceeds from sales of property, plant and equipment 102 5. Purchases of intangible assets (7,558) 6. Purchases of intestment securities (12) 7. Proceeds from sales and redemptions of investment securities 10,615 8. Payment for acquisition of business (39,166) 9. Net (increase) decrease in time deposits (exceeding 3 months) (35) 10. Other-net (52,625) III. Financing activities: (52,625) 1. Net increase (decrease) in short-term borrowings (245) 2. Dividends paid (18,468) 3. Dividends paid to minority shareholders (60) 4. Other-net (20) Net cash	· · · · · · · · · · · · · · · · · · ·	
Sub-total 63,045 18. Interest and dividends received 3,141 19. Interest paid (52) 20. Income taxes-paid (24,404) Net cash provided by operating activities 41,730 II. Investing activities: (635) 1. Purchases of short-term investment (635) 2. Proceeds from sales and redemption of short-term investments 1,453 3. Purchases of property, plant and equipment (16,443) 4. Proceeds from sales of property, plant and equipment 102 5. Purchases of intangible assets (7,558) 6. Purchases of investment securities (12) 7. Proceeds from sales and redemptions of investment securities 10,615 8. Payment for acquisition of business (39,166) 9. Net (increase) decrease in time deposits (exceeding 3 months) (35) 10. Other-net (943) Net cash used in investing activities (52,625) III. Financing activities: (245) 1. Net increase (decrease) in short-term borrowings (245) 2. Dividends paid (18,468) 3. Dividends paid to minority shareholders (60)		
18. Interest and dividends received 3,141 19. Interest paid (52) 20. Income taxes-paid (24,404) Net cash provided by operating activities 41,730 II. Investing activities: (635) 1. Purchases of short-term investment (635) 2. Proceeds from sales and redemption of short-term investments 1,453 3. Purchases of property, plant and equipment (16,443) 4. Proceeds from sales of property, plant and equipment 102 5. Purchases of intangible assets (7,558) 6. Purchases of investment securities (12) 7. Proceeds from sales and redemptions of investment securities 10,615 8. Payment for acquisition of business (39,166) 9. Net (increase) decrease in time deposits (exceeding 3 months) (35) 10. Other-net (943) Net cash used in investing activities (52,625) III. Financing activities: (245) 2. Dividends paid (18,468) 3. Dividends paid to minority shareholders (60) 4. Other-net (22) Net cash used in financing activities (18,776) IV. Foreign currency translation adjustments on cash and cash equi	Sub-total Sub-total	
19. Interest paid (52) 20. Income taxes-paid (24,404) Net cash provided by operating activities 41,730 II. Investing activities: (635) 1. Purchases of short-term investment (635) 2. Proceeds from sales and redemption of short-term investments 1,453 3. Purchases of property, plant and equipment (16,443) 4. Proceeds from sales of property, plant and equipment 102 5. Purchases of intangible assets (7,558) 6. Purchases of investment securities (12) 7. Proceeds from sales and redemptions of investment securities 10,615 8. Payment for acquisition of business (39,166) 9. Net (increase) decrease in time deposits (exceeding 3 months) (35) 10. Other-net (943) Net cash used in investing activities (52,625) III. Financing activities: (245) 2. Dividends paid (18,468) 3. Dividends paid to minority shareholders (60) 4. Other-net (22) Net cash used in financing activities (18,776) IV. Foreign currency translation adjustments on cash and cash equivalents (469) V. Net increase (decrease) i	18. Interest and dividends received	
20. Income taxes-paid (24,404) Net cash provided by operating activities 41,730 II. Investing activities: 1. Purchases of short-term investment (635) 2. Proceeds from sales and redemption of short-term investments 1,453 3. Purchases of property, plant and equipment (16,443) 4. Proceeds from sales of property, plant and equipment 102 5. Purchases of intangible assets (7,558) 6. Purchases of investment securities (12) 7. Proceeds from sales and redemptions of investment securities 10,615 8. Payment for acquisition of business (39,166) 9. Net (increase) decrease in time deposits (exceeding 3 months) (35) 10. Other-net (943) Net cash used in investing activities (52,625) III. Financing activities: 1. Net increase (decrease) in short-term borrowings (245) 2. Dividends paid (18,468) 3. Dividends paid to minority shareholders (60) 4. Other-net (22) Net cash used in financing activities (18,776) IV. Foreign currency translation adjustments on cash and cash equivalents (469) V. Net increase (decrease) in cash and cash equivalents (30,140) VI. Cash and cash equivalents at beginning of period 171,090	19. Interest paid	
Net cash provided by operating activities II. Investing activities: 1. Purchases of short-term investment 2. Proceeds from sales and redemption of short-term investments 3. Purchases of property, plant and equipment 4. Proceeds from sales of property, plant and equipment 5. Purchases of intangible assets 6. Purchases of investment securities 7. Proceeds from sales and redemptions of investment securities 8. Payment for acquisition of business 9. Net (increase) decrease in time deposits (exceeding 3 months) 10. Other-net 10. Other-net 10. Pet cash used in investing activities 11. Financing activities: 12. Dividends paid 13. Dividends paid to minority shareholders 4. Other-net 14. Other-net 15. Pet increase (decrease) in short-term borrowings 16. Section (18,468) 17. Proceeds from sales and redemptions of investment securities 18. Payment for acquisition of business 19. Net cash used in investing activities 10. Other-net 10. Othe		
II. Investing activities: 1. Purchases of short-term investment 2. Proceeds from sales and redemption of short-term investments 3. Purchases of property, plant and equipment 4. Proceeds from sales of property, plant and equipment 5. Purchases of intangible assets 6. Purchases of investment securities 7. Proceeds from sales and redemptions of investment securities 8. Payment for acquisition of business 9. Net (increase) decrease in time deposits (exceeding 3 months) 10. Other-net 10. Other-net 10. Net cash used in investing activities 11. Net increase (decrease) in short-term borrowings 2. Dividends paid 3. Dividends paid to minority shareholders 4. Other-net (20 Net cash used in financing activities (18,776) IV. Foreign currency translation adjustments on cash and cash equivalents (30,140) VI. Cash and cash equivalents at beginning of period (17,058) (16,443) (16,443) (17,558) (17,558) (17,558) (18,916) (19,716) (19,716)		
2. Proceeds from sales and redemption of short-term investments 3. Purchases of property, plant and equipment 4. Proceeds from sales of property, plant and equipment 5. Purchases of intangible assets 6. Purchases of investment securities 7. Proceeds from sales and redemptions of investment securities 8. Payment for acquisition of business 9. Net (increase) decrease in time deposits (exceeding 3 months) 10. Other-net 10. Other-net 10. Net cash used in investing activities 11. Net increase (decrease) in short-term borrowings 12. Dividends paid 13. Dividends paid 14. Other-net 15. Other-net 16. Other-net 17. Other-net 18. Payment for acquisition of business 19. Net cash used in investing activities 10. Other-net 10. Other-n		
2. Proceeds from sales and redemption of short-term investments 3. Purchases of property, plant and equipment 4. Proceeds from sales of property, plant and equipment 5. Purchases of intangible assets 6. Purchases of investment securities 7. Proceeds from sales and redemptions of investment securities 8. Payment for acquisition of business 9. Net (increase) decrease in time deposits (exceeding 3 months) 10. Other-net 10	Purchases of short-term investment	(635)
4. Proceeds from sales of property, plant and equipment 5. Purchases of intangible assets 6. Purchases of investment securities 7. Proceeds from sales and redemptions of investment securities 8. Payment for acquisition of business 9. Net (increase) decrease in time deposits (exceeding 3 months) 10. Other-net (943) Net cash used in investing activities 11. Financing activities: 12. Net increase (decrease) in short-term borrowings 13. Dividends paid 14. Other-net 15. Other-net 16. Other-net 17. Other-net 18. Foreign currency translation adjustments on cash and cash equivalents 18. Foreign currease (decrease) in cash and cash equivalents 18. Other-net 19.	2. Proceeds from sales and redemption of short-term investments	
4. Proceeds from sales of property, plant and equipment 5. Purchases of intangible assets 6. Purchases of investment securities 7. Proceeds from sales and redemptions of investment securities 8. Payment for acquisition of business 9. Net (increase) decrease in time deposits (exceeding 3 months) 10. Other-net (943) Net cash used in investing activities 11. Financing activities: 12. Net increase (decrease) in short-term borrowings 13. Dividends paid 14. Other-net 15. Other-net 16. Other-net 17. Other-net 18. Foreign currency translation adjustments on cash and cash equivalents 18. Foreign currease (decrease) in cash and cash equivalents 18. Other-net 19.	3. Purchases of property, plant and equipment	(16,443)
5. Purchases of intangible assets 6. Purchases of investment securities 7. Proceeds from sales and redemptions of investment securities 8. Payment for acquisition of business 9. Net (increase) decrease in time deposits (exceeding 3 months) 10. Other-net Net cash used in investing activities 11. Financing activities: 1. Net increase (decrease) in short-term borrowings 2. Dividends paid 3. Dividends paid (18,468) 3. Dividends paid to minority shareholders 4. Other-net Net cash used in financing activities (22) Net cash used in financing activities (33) 10. Other-net (40) 11. Foreign currency translation adjustments on cash and cash equivalents (469) 12. Net increase (decrease) in cash and cash equivalents (469) 13. Dividends paid (18,776) 14. Other-net (25) 15. Foreign currency translation adjustments on cash and cash equivalents (469) 15. Cash and cash equivalents at beginning of period (171,090)		102
6. Purchases of investment securities 7. Proceeds from sales and redemptions of investment securities 8. Payment for acquisition of business 9. Net (increase) decrease in time deposits (exceeding 3 months) 10. Other-net (943) Net cash used in investing activities 11. Net increase (decrease) in short-term borrowings 22. Dividends paid 33. Dividends paid (18,468) 34. Other-net Net cash used in financing activities (18,776) 10. Foreign currency translation adjustments on cash and cash equivalents V. Net increase (decrease) in cash and cash equivalents VI. Cash and cash equivalents at beginning of period (12) 10,615 10,6		(7,558)
7. Proceeds from sales and redemptions of investment securities 8. Payment for acquisition of business 9. Net (increase) decrease in time deposits (exceeding 3 months) 10. Other-net Net cash used in investing activities 11. Net increase (decrease) in short-term borrowings 12. Dividends paid 13. Dividends paid (18,468) 14. Other-net Net cash used in financing activities 15. Net cash used in financing activities 16. Other-net Net cash used in financing activities 17. Foreign currency translation adjustments on cash and cash equivalents 18. Topical (18,776) 19. V. Net increase (decrease) in cash and cash equivalents 10,615 (39,166) (39,166) (39,166) (35) (424)		
8. Payment for acquisition of business 9. Net (increase) decrease in time deposits (exceeding 3 months) 10. Other-net Net cash used in investing activities 11. Net increase (decrease) in short-term borrowings 12. Dividends paid 13. Dividends paid 14. Other-net 15. Net cash used in financing activities 16. Very cash used in financing activities 17. Net cash used in financing activities 18. Very cash used in financing activities 19. Very cash used in financing activities 10. Foreign currency translation adjustments on cash and cash equivalents 16. Very cash and cash equivalents at beginning of period 17. Oso	7. Proceeds from sales and redemptions of investment securities	
9. Net (increase) decrease in time deposits (exceeding 3 months) 10. Other-net Net cash used in investing activities (52,625) III. Financing activities: 1. Net increase (decrease) in short-term borrowings 2. Dividends paid 3. Dividends paid to minority shareholders 4. Other-net Net cash used in financing activities (18,776) IV. Foreign currency translation adjustments on cash and cash equivalents V. Net increase (decrease) in cash and cash equivalents VI. Cash and cash equivalents at beginning of period (35) (943) (52) (245) (18,468) (60) (18,776) (18,776) (18,776) (19,776) (10,776) (10,776) (10,776) (10,776) (11,776) (11,776)		
10. Other-net (943) Net cash used in investing activities (52,625) III. Financing activities: 1. Net increase (decrease) in short-term borrowings (245) 2. Dividends paid (18,468) 3. Dividends paid to minority shareholders (60) 4. Other-net (2) Net cash used in financing activities (18,776) IV. Foreign currency translation adjustments on cash and cash equivalents (469) V. Net increase (decrease) in cash and cash equivalents (30,140) VI. Cash and cash equivalents at beginning of period 171,090		, , ,
Net cash used in investing activities (52,625) III. Financing activities: 1. Net increase (decrease) in short-term borrowings (245) 2. Dividends paid (18,468) 3. Dividends paid to minority shareholders (60) 4. Other-net (2) Net cash used in financing activities (18,776) IV. Foreign currency translation adjustments on cash and cash equivalents (469) V. Net increase (decrease) in cash and cash equivalents (30,140) VI. Cash and cash equivalents at beginning of period 171,090	10. Other-net	
1. Net increase (decrease) in short-term borrowings (245) 2. Dividends paid (18,468) 3. Dividends paid to minority shareholders (60) 4. Other-net (2) Net cash used in financing activities (18,776) IV. Foreign currency translation adjustments on cash and cash equivalents (469) V. Net increase (decrease) in cash and cash equivalents (30,140) VI. Cash and cash equivalents at beginning of period 171,090	Net cash used in investing activities	
1. Net increase (decrease) in short-term borrowings (245) 2. Dividends paid (18,468) 3. Dividends paid to minority shareholders (60) 4. Other-net (2) Net cash used in financing activities (18,776) IV. Foreign currency translation adjustments on cash and cash equivalents (469) V. Net increase (decrease) in cash and cash equivalents (30,140) VI. Cash and cash equivalents at beginning of period 171,090	III. Financing activities:	
3. Dividends paid to minority shareholders 4. Other-net (2) Net cash used in financing activities (18,776) IV. Foreign currency translation adjustments on cash and cash equivalents V. Net increase (decrease) in cash and cash equivalents VI. Cash and cash equivalents at beginning of period (60) (18,776) (18,776) (18,776) (19	=	(245)
3. Dividends paid to minority shareholders 4. Other-net (2) Net cash used in financing activities (18,776) IV. Foreign currency translation adjustments on cash and cash equivalents V. Net increase (decrease) in cash and cash equivalents VI. Cash and cash equivalents at beginning of period (60) (18,776) (18,776) (18,776) (19	2. Dividends paid	(18,468)
4. Other-net Net cash used in financing activities (18,776) IV. Foreign currency translation adjustments on cash and cash equivalents V. Net increase (decrease) in cash and cash equivalents VI. Cash and cash equivalents at beginning of period (2) (18,776) (469) (30,140) (171,090)		
IV. Foreign currency translation adjustments on cash and cash equivalents (469) V. Net increase (decrease) in cash and cash equivalents (30,140) VI. Cash and cash equivalents at beginning of period 171,090		
IV. Foreign currency translation adjustments on cash and cash equivalents (469) V. Net increase (decrease) in cash and cash equivalents (30,140) VI. Cash and cash equivalents at beginning of period 171,090	Net cash used in financing activities	······
V. Net increase (decrease) in cash and cash equivalents(30,140)VI. Cash and cash equivalents at beginning of period171,090		
VI. Cash and cash equivalents at beginning of period 171,090		

Segment Information (for reference) (1) Business Segment Information

Three months ended September 30, 2007

					(millions of yen)
	Pharma- ceuticals	Other	Total	Eliminations and Corporate	Consolidated
					-
Total sales	180,648	11,595	192,244	[5,460]	186,783
Operating expenses	149,324	10,943	160,267	[4,360]	155,907
Operating income	31,324	651	31,976	[1,100]	30,875

Six months ended September 30, 2007

(millions of yen)

	Pharma- ceuticals	Other	Total	Eliminations and Corporate	Consolidated
Sales (1) Sales to external customers (2) Intersegment sales	351,449	11,368	362,817	-	362,817
	95	9,215	9,310	[9,310]	-
Total sales Operating expenses	351,544	20,583	372,127	[9,310]	362,817
	293,337	19,594	312,932	[7,175]	305,756
Operating income	58,206	989	59,195	[2,134]	57,061

Note 1: The Company classifies consolidated operations into two segments: 'Pharmaceuticals', which includes prescription pharmaceuticals, and 'Other', which encompasses all operations other than pharmaceuticals.

Note 2: Major products in each segment are as follows:

Business segment	Major products
Pharmaceuticals	Prescription pharmaceuticals, Consumer health care products, Diagnostic pharmaceuticals, etc.
Other	Food additives, Chemicals, Machinery, Others


(2) Geographical Segment Information

Three months ended September 30, 2007

(millions of yen)

Japan North America Europe and Total others

Six months ended September 30, 2007



[Forward-looking Statements and Risk Factors]

Materials and information provided in this financial disclosure may contain "forward-looking statements" based on current expectations, forecasts, estimates, business goals and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions, such as interest rate and currency exchange fluctuations.

Risks that may cause significant fluctuations in the consolidated results of the Company or have a material effect on decisions of shareholders are described below. These are risk factors that have been identified and assessed as of the disclosure date of the Financial Report. Risk factors associated with our business include, but are not limited to, challenges arising out of global expansion, uncertainties in new drug development, risks related to strategic alliances with partners, risks related to the acquisition of MGI PHARMA, INC., healthcare cost-containment measures, intensified competition with generic drugs, intellectual properties, possible incidence of adverse events, compliance with laws and regulations, litigations, closure or shutdown of factories, safety issues of raw materials used, outsourcing-related risks, environmental issues, IT security/information management, and conditions of financial markets, foreign exchange fluctuations, and internal control system.

		Page
1.	Consolidated Financial Highlights	 1
2.	Consolidated Statements of Operation	 3
3.	Consolidated Statements of Cash Flows	 4
4.	Financial Results by Business Segment	 5
5.	Consolidated Balance Sheets	 10
6.	Consolidated Changes in Quarterly Results	 12
7.	Non-Consolidated Financial Highlights	 16
8.	Stock Information	 21
9.	Consolidated Subsidiaries - Associated Companies	 23
10.	Personnel Information	 25
11.	Major R&D Pipeline Candidates	 26
12.	Major Events	 32

1. Consolidated Financial Highlights 1) Statements of Operation Data (billions of yen)

2) Statements of Cash Flows Data

(billions of yen)

Years Ended/Ending March 31	Six mon	Six months ended Sep 30		Full
2Q Apr - Sep	2008	2009	Inc./	2008
			(Dec.)	
Net cash provided by operating activities	41.7	69.3	27.6	73.2
Net cash used in investing activities	(52.6)	(17.0)	35.6	(476.4)
Net cash provided by (used in) financing activities	(18.8)	(25.5)	(6.8)	375.4
Cash and cash equivalents at end of period	141.0	142.1	1.1	120.0
Free cash flows	(21.3)	46.2	67.6	(415.9)

^{* &}quot;Free cash flows" = "Net cash provided by operating activities" - "Capital expenditures (including acquisition)"

3) Balance Sheets Data

(billions of yen)

	20	2008	
	Mar 31	Sep 30	(Dec.)
Total assets	1,123.9	1,156.5	32.6
Total liabilities	670.1	691.6	21.5
Bonds and debentures	1.0	120.7	119.7
Short-term & long-term borrowings	412.8	285.5	(127.3)
Total equity	453.8	464.9	11.1
Shareholders' Equity	448.9	460.0	11.1
Shareholders' Equity/Total assets (%)	39.9	39.8	(0.2)

4) Capital Expenditures and Depreciation/Amortization

(billions of yen)

., capital experience and expressions and an expression and expression and an expres			(2			
Years Ended/Ending March 31	Six mont	Six months ended Sep 30			Full	
2Q Apr - Sep	2008	2009	Inc./	2008	2009	
			(Dec.)		est.	
Capital expenditures	81.5	20.8	(60.7)	434.0	43.0	
Property, plant and equipment	13.6	17.9	4.2	39.8	35.0	
Intangible assets	67.9	3.0	(64.9)	394.3	<u>8.0</u>	
Depreciation/Amortization	15.4	24.9	9.5	34.6	57.5	

^{*} Capital expenditures include the increase of asset by acquisition of Morphotek, Inc. and MGI PHARMA, INC.. * "Depreciation/Amortization" value includes amortization for "Intangible assets".

2. Consolidated Statements of Operation

					(billions	of yen)	
Years Ended/Ending March 31		Six	months er	nded Sep	30		<explanations></explanations>
2Q Apr - Sep	2008	Sales	2009	Sales	YOY	Inc./	
		%		%	%	(Dec.)	
Net sales	362.8	100.0	398.8	100.0	109.9	36.0	Net sales
Cost of sales	54.7	15.1	79.2	19.9	144.8	24.5	<pre><increase factors=""> Increase in sales of</increase></pre>
(Reversal of) Provision for sales returns-net	(0.1)	(0.1)	0.0	0.0		0.1	ARICEPT, Contribution of
Gross profit	308.2	85.0	319.6	80.1	103.7	11.4	ALOXI and DACOGEN
R&D expenses	63.8	17.6	78.0	19.6	122.2	14.2	R&D expenses
SG&A expenses	187.3	51.6	195.0	48.9	104.1	7.7	<pre><increase factors=""> Progress of clinical studies</increase></pre>
Operating income	57.1	15.7	46.5	11.7	81.6	(10.5)	. regrees or aminoal studies
Non-operating income	3.3	0.9	2.7	0.7		(0.6)	
Non-operating expenses	0.8	0.2	5.7	1.4		4.8	Non-operating expenses
Ordinary income	59.6	16.4	43.6	10.9	73.2	(16.0)	<pre><increase factor=""> Increase in interest paid</increase></pre>
Special gain	2.3	0.6	2.0	0.5		(0.2)	due to increase of borrowings
Special loss	1.1	0.3	2.0	0.5		0.9	borrowings
Income before income taxes and minority interests	60.7	16.7	43.6	10.9	71.8	(17.1)	
Income taxes-current	25.4	7.0	24.6	6.2	96.9	(8.0)	
Income taxes-deferred	(4.4)	(1.2)	(10.0)	(2.5)		(5.6)	
Minority interests in net income	0.4	0.1	0.3	0.1		(0.1)	
Net income (loss)	39.4	10.8	28.7	7.2	73.0	(10.6)	
<cash ability="" generating=""></cash>							
Net income (loss)	39.4	10.8	28.7	7.2	73.0	(10.6)	
Depreciation of PP&E and amortization of intangible assets	13.9		14.0			0.1	
Amortization of intangible assets obtained by acquisition	1.4		10.9			9.5	
In-process R&D expenses	0.6		-			(0.6)	
Amortization of goodwill	0.1		4.7			4.6	
Impairment loss on long-lived assets	0.0		-			(0.0)	
Cash income	55.3	15.3	58.3	14.6	105.3	2.9	

3. Consolidated Statements of Cash Flows

(billions of yen)

		(, - ,	
Years Ended/Ending March 31				<explanations></explanations>
2Q Apr - Sep	2008	2009	Inc./	
			(Dec.)	

Operating activities:

Income before income taxes and minority interests in net income

4. Financial Results by Business Segment

1) Consolidated Net Sales by Business Segment

(billions of yen)

Years Ended/Ending March 31			Full
2Q Apr - Sep	2008	2009	2008
Net sales to customers	362.8	398.8	734.3
Pharmaceuticals	351.4	388.5	711.8euticals

3) Geographical Segment Information

(1) Consolidated Net Sales by Geographical Segment

(billions of yen)

Years Ended/Ending March 31			Full
2Q Apr - Sep	2008	2009	2008
Net sales to customers	362.8	398.8	734.3
Japan	157.4	166.3	312.7
North America	164.2	187.4	339.4
Europe	27.3	29.1	54.4
China	4.7	6.0	9.5
Asia and others	9.2	10.1	18.3
Overseas sales	205.4	232.5	421.6
Overseas sales (%)	56.6	58.3	57.4

^{*} Net sales to external customers for each segment.

(2) Consolidated Operating Income by Geographical Segment

(billions of yen)

Years Ended/Ending March 31			Full
2Q Apr - Sep	2008	2009	2008
Operating income	57.1	46.5	17.7
Japan	45.8	39.1	80.5
North America	9.7	3.7	(66.9)
Europe	0.9	2.2	1.8
China	1.1	1.3	2.0
Asia and others	2.0	2.4	3.7
Eliminations and corporate	(2.5)	(2.2)	(3.3)

4) Overseas Sales

(billions of yen)

Years Ended/Ending March 31			Full
2Q Apr - Sep	2008	2009	2008
Net sales	362.8	398.8	734.3
Overseas sales	222.2	247.3	454.6
North America	169.5	192.4	350.4
Europe	37.0	37.0	73.1
China	4.7	6.0	9.5
Asia and others	11.1	11.9	

5) Global Product Sales by Geographical Area(Eisai Territory Sales)

(1) ARICEPT (Alzheimer's disease treatment)

Years Ended/Ending March 31		Six months end	led Sep 30	Full
2Q Apr - Sep		2008	2009	2008
Area				
Japan	¥ Billions	30.0	38.3	62.3
U.S.	¥ Billions	89.5	93.3	186.9
	[U.S. \$ Millions]	[750]	[879]	[1,635]
Europe Total	¥ Billions	17.3	16.7	33.3
UK	¥ Billions	0.6	2.0	1.4
	[UK £ Millions]	[3]	[10]	[6]
France	¥ Billions	12.9	10.1	24.3
	[Euro Millions]	[79]	[62]	[151]
Germany	¥ Billions	3.8	4.5	7.6
	[Euro Millions]	[23]	[28]	[47]
China	¥ Billions	0.4	0.4	1.2
	[Chinese RMB Millions]	[25]	[29]	[75]
Asia (excluding Japan and China)	¥ Billions	3.6	4.0	7.4
Total	¥ Billions	140.9	152.6	291.0

^{*} Sales forecast for Eisai sales territories for the year ending on March 31, 2009 is \(\frac{\pmax}{314.0 \text{ billion}}\).

(2) ACIPHEX/PARIET (Proton pump inhibitor)

Years Ended/Ending March 31		Six months ended Sep 30	Full
2Q Apr - Sep		2008 2009	2008
Area			
Japan	¥ Billions	18.3 21.7	37.1
U.S.	¥ Billions	66.4 52.9	124.7
	[U.S. \$ Millions]	[556] [498]	[1,091]
Europe Total	¥ Billions	4.6 5.1	8.6
UK	¥ Billions	1.5 1.3	2.2
	[UK £ Millions]	[6] [7]	[9]
Germany	¥ Billions	0.9 1.3	1.8
	[Euro Millions]	[5] [8]	[11]
Italy	¥ Billions	2.3 2.3	4.5
	[Euro Millions]	[14] [14]	[28]
China	¥ Billions	0.4 0.3	0.7
	[Chinese RMB Millions]	[24] [21]	[43]
Asia (excluding Japan and China)	¥ Billions	2.6 2.6	4.8
Total	¥ Billions	92.2 82.6	175.9

^{*} Sales forecast for Eisai sales territories for the year ending on March 31, 2009 is \pm 161.0 billion.

 April 1, 2007 to September 30, 2007
 15.66 yen/Chinese RMB

 April 1, 2008 to September 30, 2008
 15.38 yen/Chinese RMB

 April 1, 2007 to March 31, 2008
 15.30 yen/Chinese RMB

^{*} Average exchange rate of Japanese yen to Chinese RMB

Years Ended/Ending March 31	Six months end	Six months ended Sep 30		
2Q Apr - Sep	2008	2009	2008	
Net sales	362.8	398.8	734.3	
SG&A expenses	187.3	195.0	372.3	
Personnel expenses	37.2	42.2	77.1	
Marketing promotion expenses	123.1	121.0	241.9	
Administrative expenses and others	27.0	31.8	53.3	
Ratio of SG&A expenses to net sales (%)	51.6	48.9	50.7	

7) Eisai Inc. (U.S.)

· / =:==: (-:-:/				
Years Ended/Ending March	ears Ended/Ending March 31		ded Sep 30	Full
2Q Apr - Sep		2008	2009	2008
Net sales	¥ Billions	166.1	172.8	332.7
	[U.S. \$ Millions]	[1,392]	[1,629]	[2,911]
Operating income	¥ Billions	10.7	12.0	25.2
	[U.S. \$ Millions]	[90]	[114]	[221]
Net income	¥ Billions	7.5	7.8	17.1
	[U.S. \$ Millions]	[63]	[74]	[149]
Operating income before royalty deduction	¥ Billions	41.5	42.0	87.7
	[U.S. \$ Millions]	[348]	[396]	[767]

^{*}Starting July 2008, the sales operation of MGI PHARMA INC. has been integrated to Eisai Inc. As a result, the net sales of U.S. \$142 million (¥15.1 billion) by MGI PHARMA INC. were included to the above figures.

5. Consolidated Balance Sheets

1) Consolidated Balance Sheets < Assets>

1) Consolidated Balance Sheet	s <asset< th=""><th>s></th><th></th><th></th><th>(billions</th><th>of yen)</th><th></th></asset<>	s>			(billions	of yen)	
					Change	Inc./	<explanations></explanations>
	Mar 31	%	Sep 30	%	%	(Dec.)	
Current assets:							
Cash and cash in banks	68.6		65.0			(3.6)	
Notes and accounts receivable-trade	172.1		180.8			8.6	
Short-term investments	56.3		83.8			27.5	
Inventories	58.1		58.7			0.6	
Deferred tax assets	35.4		34.9			(0.5)	
Other	25.4		21.3			(4.0)	
Allowance for doubtful receivables	(0.3)		(0.3)			(0.0)	
Total current assets	415.6	37.0	444.2	38.4	106.9	28.6	
Non-current assets:							
Property, plant and equipment:							
Buildings and structures	70.8		70.3			(0.5)	
Machinery, equipment and vehicles	23.1		22.1			(1.0)	
Land	20.8		20.7			(0.1)	
Construction in progress	19.8		31.0			11.2	
Other	12.6		13.5			0.9	
Total property, plant and equipment	147.1	13.1	157.6	13.6	107.1	10.5	
Intangible assets:							
Goodwill	178.7		177.9			(0.8)	

2) Consolidated Balance Sheets < Liabilities and Equity>	(billions
--	-----------

2) Consolidated Balance Sheet						s of yen)		
	NA 04		800	0/	Change	Inc./	<explanations></explanations>	
	Mar 31	%	Sep 30	%	%	(Dec.)		
Current liabilities:								
Notes and accounts payable-trade	18.3		19.5			1.2		
Short-term borrowings	362.8		3.0			(359.8)		
Accounts payable-other/accrued expenses etc.	116.7		126.4			9.8	borrowings <decrease factor=""> Shift to Bonds and</decrease>	
Income taxes payable	16.1		23.1			7.0	debenture and Long-	
Reserve for sales rebates	23.3		29.7			6.3	term borrowings	
Other	6.0		8.2			2.2		
Total current liabilities	543.2	48.3	209.9	18.1	38.6	(333.3)		
Long-term liabilities:							Bonds and debentures	
Bonds and debentures	0.8		120.7			119.8	<pre><increase factor=""> Issuance of unsecured</increase></pre>	
Long-term borrowings	50.0		282.5			232.5	straight bonds	
Deferred tax liabilities	40.2		42.3			2.1	Long-term	
Liability for retirement benefits	24.1		23.1			(1.0)	borrowings	
Retirement allowances for directors	2.1		2.3			0.1	<increase factor=""> Financing for</increase>	
Other	9.6		10.9			1.3	acquisition	
Total long-term liabilities	127.0	11.3	481.8	41.7	379.5	354.8		
Total liabilities	670.1	59.6	691.6	59.8	103.2	21.5		
Owners' equity:								
Common stock	45.0		45.0			-		
Capital surplus	57.0		57.0			(0.0)		
Retained earnings	416.0		424.3			8.3		
Treasury stock	(39.7)		(39.7)			0.0		
Total owners' equity	478.2	42.5	486.6	42.1	101.7	8.3		
Net unrealized gain (loss) and translation adjustments: Net unrealized gain (loss) on available-	9.5		4.8			(4.7)		
for-sale securities Deferred gain (loss) on derivatives under hedge accounting	-		(0.0)			(0.0)		
Foreign currency translation adjustments	(38.9)		(31.3)			7.5		
Total net unrealized gain (loss) and translation adjustments	(29.4)	(2.6)		(2.3)		2.8		
Stock acquisition rights	0.6	0.1	0.6	0.0	103.3	0.0		
Minority interests	4.4	0.4	4.3	0.4	98.4	(0.1)		
Total equity	453.8	40.4	464.9	40.2	102.4	11.1		
Total liabilities and equity	1,123.9	100.0	1,156.5	100.0	102.9	32.6		

6. Consolidated Changes in Quarterly Results

1) Statements of Operation Data

(billions of yen)

Years Ended/Ending March 31						
	First	Second	Third	Fourth	First	Second
	Quarter	Quarter	Quarter	Quarter	Quarter	Quarter
Net sales	176.0	186.8	196.7	174.7	195.8	203.0
Cost of sales	27.5	27.1	28.9	35.3	39.4	39.9
R&D expenses	30.5	33.3	35.7	125.9	35.7	42.3
SG&A expenses	91.8	95.5	96.6	88.4	96.7	98.4
Operating income (loss)	26.2	30.9	35.5	(74.8)	24.1	22.5
Non-operating income & expenses	2.2	0.3	1.2	(2.6)	(0.2)	(2.7)

3) Balance Sheets Data

,						
<assets></assets>					(billio	ns of yen)
	Jun 30	Sep 30	Dec 31	Mar 31	Jun 30	Sep 30
Current assets	396.0	420.9	430.9	415.6	433.4	444.2
Property, plant and equipment	135.3	137.5	141.4	147.1	155.0	157.6
Intangible assets	104.0	121.6	120.4	417.7	430.3	410.8
Investments and other assets	150.4	137.7	140.6	143.6	146.6	144.0
Non-current assets	389.7	396.8	402.4	708.4	731.9	712.3
Total assets	785.7	817.6	833.3	1,123.9	1,165.3	1,156.5
<liabilities and="" equity=""> (billion</liabilities>						
	Jun 30	Sep 30	Dec 31	Mar 31	Jun 30	Sep 30
Current liabilities	180.6	191.8	205.7	543.2	367.1	

U.S.	¥ Billions	41.5	48.0	48.0	49.4	43.4	49.9
	[U.S. \$ Millions]	[343]	[407]	[423]	[463]	[415]	[464]
Europe	¥ Billions	9.2	8.1	9.0	6.9	8.0	8.7
UK	¥ Billions	0.3	0.3	0.4	0.3	0.7	1.3
	[UK £ Millions]	[1]	[1]	[2]	[2]	[4]	[6]
France	¥ Billions	7.0	5.9	6.6	4.8	5.1	5.0
	[Euro Millions]	[43]	[36]	[40]	[31]	[31]	[31]
Germany	¥ Billions	1.9	1.9	2.0	1.8	2.1	2.4
	[Euro Millions]	[12]	[12]	[12]	[11]	[13]	[15]
China	¥ Billions	0.0	0.3	0.3	0.5	0.1	0.3
	[Chinese RMB Millions]	[3]	[22]	[17]	[33]	[9]	[20]
Asia (excluding Japan and China)	¥ Billions	1.7	1.9	2.0	1.8	2.0	2.0
Total	¥ Billions	67.3	73.5	78.2	71.9	72.9	79.6

6) ACIPHEX/PARIET Sales by Area (Eisai Territory Sales)

Years Ended/Ending March 31			200		2009		
	-	First	Second	Third	Fourth	First	Second
		Quarter	Quarter	Quarter	Quarter	Quarter	Quarter
Japan	¥ Billions	8.9	9.3	11.2	7.6	11.0	10.6
U.S.	¥ Billions	31.8	34.6	33.1	25.2	25.9	27.0
	[U.S. \$ Millions]	[263]	[293]	[292]	[243]	[248]	[251]
Europe	¥ Billions	2.5	2.1	1.9	2.0	2.5	2.6
UK	¥ Billions	0.8	0.7	0.4	0.4	0.6	0.7
	[UK £ Millions]	[3]	[3]	[2]	[2]	[3]	[3]
Germany	¥ Billions	0.5	0.3	0.4	0.5	0.6	0.7
	[Euro Millions]	[3]	[2]	[2]	[3]	[4]	[4]
Italy	¥ Billions	1.2	1.1	1.1	1.2	1.2	1.2
	[Euro Millions]	[7]	[7]	[7]	[7]	[7]	[7]
China	¥ Billions	0.2	0.2	0.1	0.1	0.1	0.2
	[Chinese RMB Millions]	[14]	[10]	[9]	[10]	[9]	[13]
Asia (excluding Japan and China)	¥ Billions	1.4	1.2	1.3	1.0	1.3	1.3
Total	¥ Billions	44.9	47.3	47.7	36.0	40.8	41.7

7) METHYCOBAL Sales by Area (Eisai Territory Sales)

Years Ended/Ending March 31			2008				4j0 32 899 330([7])Tj/TT4 1 Tf8.28			
		First	Second	Third	Fourth	First	Second			
		Quarter	Quarter	Quarter	Quarter	Quarter	Quarter			
Japan	¥ Billions	8.2	8.0	9.1	6.4	8.3	7.7			
Asia (including China)	¥ Billions	1.8	1.8	1.7	1.7	2.4	2.4			
Total	¥ Billions	10.1	9.8	10.8	8.1	10.7	10.1			

8) ALOXI Sales by Area (Eisai Territory Sales)

Years Ended/Endin	g March 31		2008				9
		First	Second	Third	Fourth	First	Second
		Quarter	Quarter	Quarter	Quarter	Quarter	Quarter
U.S.	¥ Billions	-	-	-	6.5	9.5	9.5
	[U.S. \$ Millions]	[-]	[-]	[-]	[62]	[90]	[88]

9) DACOGEN Sales by Area (Eisai Territory Sales)

Years Ended/Endin		2008		2009			
		First	Second	Third	Fourth	First	Second
		Quarter	Quarter	Quarter	Quarter	Quarter	Quarter
U.S.	¥ Billions	-	-	-	2.7	4.4	4.3
	[U.S. \$ Millions]	[-]	[-]	[-]	[26]	[42]	[40]

10) ZONEGRAN Sales by Area (Eisai Territory Sales)

Years Ended/Ending March 31		2008				2009	
		First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter	Second Quarter
U.S.	¥ Billions [U.S. \$ Millions]	0.7 [6]	0.7 [6]	0.4 [4]	0.4 [4]	0.5 [4]	0.6 [5]
Europe	¥ Billions	0.7	0.8	0.9	0.8	1.0	1.0
Asia	¥ Billions	0.0	0.0	0.0	0.1	0.1	0.1
Total	¥ Billions	1.5	1.6	1.4	1.2	1.5	1.6

11) Eisai Inc. (U.S.)

Years Ended/Ending March 31		2008				2009	
		First	Second	Third	Fourth	First	Second
		Quarter	Quarter	Quarter	Quarter	Quarter	Quarter
Net sales	¥ Billions	77.8	88.3	86.7	79.9	74.8	98.0
	[U.S. \$ Millions]	[644]	[748]	[764]	[756]	[716]	[913]
Operating income	¥ Billions	3.6	7.1	7.4	7.1	4.0	8.1
	[U.S. \$ Millions]	[29]	[60]	[65]	[66]	[39]	[75]
Net income	¥ Billions	2.6	4.9	5.0	4.6	2.6	5.2
	[U.S. \$ Millions]	[22]	[41]	[44]	[43]	[25]	[48]
Operating income before	¥ Billions	18.0	23.5	23.6	22.6	18.1	23.9
royalty deduction	[U.S. \$ Millions]	[149]	[199]	[207]	[212]	[174]	[222]

^{*}Starting July 2008, the sales operation of MGI PHARMA INC. has been integrated to Eisai Inc. As a result, the net sales of U.S. \$142 million (¥15.1 billion) by MGI PHARMA INC. were included to the above figures.

7. Non-Consolidated Financial Highlights

1) Non-Consolidated Financial Highlights

(1) Statements of Income Data

(billions of yen)

Years Ended/Ending March 31					
2Q Apr - Sep	2008	2009	YOY	2008	2009
			%		est.
Net sales	194.9	204.1	104.8	389.2	<u>405.0</u>
Cost of sales	39.1	41.3	105.8	76.0	<u>79.0</u>
R&D expenses	61.9	71.0	114.7	134.0	<u>141.5</u>
SG&A expenses	52.2	56.9	109.0	106.1	<u>114.5</u>
Operating income	41.7	34.9	83.7	73.1	70.0
Ordinary income	41.9	32.3	77.0	71.0	<u>62.5</u>
Net income	28.2	26.0	92.3	46.0	<u>46.5</u>

^{* &}quot;Cost of sales" includes "(Reversal of) Provision for sales returns-net".

(2) Statements of Cash Flows Data

(billions of yen)

<u> </u>			(2	
Years Ended/Ending March 31				Full
2Q Apr - Sep	2008	2009	Inc./	2008
			(Dec.)	
Net cash provided by operating activities	22.4	31.6	9.1	36.7

2) Net Sales by Business Segment

(billions of yen)

Years Ended/Ending March 31					
2Q Apr - Sep	2008	2009	YOY	2008	2009
			%		est.
Net sales	194.9	204.1	104.8	389.2	<u>405.0</u>
Prescription pharmaceuticals	117.0	129.0	110.3	231.8	256.5

Years Ended/Ending March 31					
2Q Apr - Sep	2008	2009	YOY	2008	2009
Description / Product			%		est
Alzheimer's disease treatment ARICEPT	30.0	38.3	127.4	62.3	<u>77.0</u>
Proton pump inhibitor <i>PARIET</i>	18.3	21.7	118.7	37.1	<u>43.5</u>
Peripheral neuropathy treatment METHYCOBAL	16.2	16.0	98.7	31.7	30.0
Gastritis/gastric ulcer treatment SELBEX	9.4	8.2	87.4	18.2	16.0
Osteoporosis treatment ACTONEL	4.8	4.4	90.9	8.2	10.0
Muscle relaxant <i>MYONAL</i>	4.2	4.0	95.8	8.0	<u>7.5</u>
Non-ionic contrast medium IOMERON	4.1	3.7	90.4	7.9	7.5
Osteoporosis treatment GLAKAY	3.5	2.9	81.9	6.4	5.5
Genetically engineered glucagon preparation GLUCAGON G NOVO	2.0	1.9	94.1	3.9	3.5
Long-acting isosorbide denigrate preparation NITOROL-R	1.8	1.6	89.2	3.4	3.0
Others	22.7	26.4	116.5	44.7	<u>53.0</u>
Prescription pharmaceuticals total	117.0	129.0	110.3	231.8	<u>256.5</u>
orts b y Products				(hillion	ns of yen)
Years Ended/Ending March 31				ioiiiid)	is or yerr,
2Q Apr - Sep	2008	2009	YOY	2008	2009
Description / Product			%		est
ARICEPT	14.2	14.1	99.2	28.1	24.5
ACIPHEX/PARIET	12.9	11.1	86.0	25.1	21.0
Others	3.4	3.8	109.3	7.5	<u>7.0</u>
Exports total	30.5	28.9	94.8	60.7	<u>52.5</u>
6) Consumer Health Care Products				(billior	ns of yen
Years Ended/Ending March 31					
2Q Apr - Sep	2008	2009	YOY	2008	2009
Description / Product			%		est
√itamin B₂ preparation CHOCOLA BB Group	4.7	5.1	107.2	9.5	10.0
Active-type Vitamin B12 <i>NABOLIN</i> Group	1.1	1.1	100.7	2.3	2.5

8.0

8.0

1.8

9.5

94.0

101.9

85.1

100.0

1.7

1.6

5.1

20.1

1.5

1.5

4.5

20.0

8.0

0.7

2.1

9.5

JUVELUX / Natural Vitamin E preparation

Stomach ache and heartburn treatment

Consumer health care products total

Vitamin-E Group

SACLON Group

Others

7) Gross Profit/Manufacturing Cost (1) Breakdown of Cost of Sales

(1) Breakdown of Cost of Sales Years Ended/Ending March 31		(2	ons of yen) Full
2Q Apr - Sep	2008	2009	2008
Net sales	194.9	204.1	389.2
Cost of sales	39.2	41.3	76.1
Beginning inventory (+)	15.2	15.9	15.2
Manufacturing cost (+)	19.0	19.3	38.3
Product purchase (+)	13.1	16.3	26.1
Account transfer (+)	7.0	6.1	12.4
Ending inventory (-)	15.2	16.3	15.9
COGS ratio to net sales (%)	20.1	20.2	19.6
(Reversal of) provision for sales returns	(0.1)	(0.2)	(0.1)
Gross profit	155.8	162.6	313.2
(2) Breakdown of Manufacturing Cost		(billid	ons of yen)
Years Ended/Ending March 31			Full
2Q Apr - Sep	2008	2009	2008
Total manufacturing cost	22.1	22.4	44.2
Raw materials	7.7	8.3	14.7
Labor cost	5.5	5.6	10.9
Expenses	8.8	8.5	18.6
Beginning inventory of semi-finished goods and work-in-process (+)	9.4	9.3	9.4
Ending inventory of semi-finished goods and work-in-process (-)	9.4	9.9	9.3
Account transfer (+)	(3.0)	(2.5)	(5.9)
Manufacturing cost	19.0	19.3	38.3
8) Overseas R&D Expenses/SG&A Expenses		(billio	ons of yen)
Years Ended/Ending March 31	Six months end	led Sep 30	Full
2Q Apr - Sep	2008	2009	2008
R&D expenses	61.9	71.0	134.0
Overseas R&D expenses	35.0	41.7	77.1
[Ratio of overseas R&D expenses to R&D expenses] (%)	[56.5]	[58.7]	[57.5]
SG&A expenses	52.2	56.9	106.1
Personnel expenses	15.8	16.5	31.5
Marketing expenses	22.7	26.9	46.2
Administrative expenses and others	13.7	13.5	28.5
SG&A expenses (including R&D expenses)	114.1	127.9	240.1
		-	

8. Stock Information

Total Number of

Authorized Shares

1) Issued Stock and Shareholder Information

Number of

Shares Outstanding

As of September 30, 2008

Number of Average Number of
Shareholders (persons) (shares)

(Snares	(Strates)	(Shares)	(persons)	(Shares)
1,100,000,000	296,566,949	11,656,846	62,747	4,726

[Number of

Treasury Stock]

2) Top 10 Shareholders

As of September 30, 2008

z) rop ro shareholders	As of September 30, 2006		
Name			
	(1,000 shares)		
Nippon Life Insurance Company	15,344	5.17	

5) Breakdown of Shareholders Holding Size/Number of Shareholders (persons) 2008 2008 Inc./ % % Mar 31 Sep 30 (Dec.) 52 0.1 50 0.1 1 million shares and over (2) 100,000 ~ 999,999 shares 184 0.3 162 0.3 (22)10,000 ~ 99,999 shares 801 1.2 818 1.3 17 1,000 ~ 9,999 shares 12,452 12,414 (38)18.6 19.8 100 ~ 999 shares 49,160 73.4 44,937 (4,223)71.6

4,281

66,930

6.4

100.0

4,366

62,747

7.0

100.0

85

(4,183)

6) Breakdown by Shareholder Holding Size/Number of Shares Held					000 shares)
	2008	%	2008	%	Inc./
	Mar 31	/0	Sep 30	/0	(Dec.)
1 million shares and over	181,692	61.3	191,265	64.5	9,573
100,000 ~ 999,999 shares	57,209	19.3	47,538	16.0	(9,670)
10,000 ~ 99,999 shares	20,176	6.8	21,020	7.1	843
1,000 ~ 9,999 shares	26,253	8.8	26,064	8.8	(189)
100 ~ 999 shares	11,056	3.7	10,499	3.5	(557)
less than 100 shares	177	0.1	177	0.1	(0)
Total	296,566	100.0	296,566	100.0	-

^{*} Number of shares less than one thousand has been omitted.

less than 100 shares

Total

(2) Subsidiaries in Japan (11 companies)

As of September 30, 2008

Company Name	Location	Common Stock	Equity (%) Ownership	Description of Operations
Sanko Junyaku Co., Ltd.	Tokyo	5,262 million yer	n 100.00%	Diagnostic product prod./sales
Sannova Co., Ltd.	Gunma Pref.	926 million yer	n 79.95%	Pharma. production/sales
Elmed Eisai Co., Ltd.	Tokyo	450 million yer	100.00%	Pharma. sales
Eisai Food & Chemicals Co., Ltd.	Tokyo	101 million yei	100.00%	Food additives/chemicals sales
Eisai Machinery Inc.	Tokyo	100 million yei	100.00%	Pharma. machinery prod./sales
KAN Research Institute, Inc.	Hyogo Pref.	70 million yei	100.00%	Basic research
Eisai Distribution Co., Ltd.	Kanagawa Pref.	60 million yei	100.00%	Pharma. distribution
Palma Bee'Z Research Institute Co., Ltd.	Tokyo	50 million yei	100.00%	Diagnostic product research
Eisai R&D Management Co., Ltd.	Tokyo	11 million yei	100.00%	Management of drug development/research
Sunplanet Co., Ltd.	Tokyo	455 million yer	n 84.93%	Administrative/Catering/Printing service/Real estate management
Eisai Seikaken Co., Ltd.	Tokyo	50 million yei	n 70.00%	Agro-chemical prod./sales

^{*} The whole shares of Clinical Supply Co., Ltd. held by Eisai Co., Ltd. were transferred in June 2008.

2) Equity in Earnings in Associated Companies (1 company)

As of September 30, 2008

Company Name	Location	Common Stock	Equity (%) Ownership	Description of Operations
Bracco-Eisai Co., Ltd.	Tokyo	340 million yen	49.00%	Contrast media import/prod./sales

^{*} Fiscal year of Bracco-Eisai Co., Ltd. ends on December 31.

^{*} Fractions figures in "Common Stock" are rounded down.

^{*} Fractions figures in "Common Stock" are rounded down.

10. Personnel Information

1) Consolidated Personnel Information

(persons)

March 31	2006	2007	2008	2008 Sep 30
Total employees	9,081	9,649	10,686	11,035
Japan	5,144	5,334	5,453	5,641
U.S.	1,787	1,975	2,699	2,711
Europe	650	765	861	918
China	742	777	834	921
Asia (excluding Japan and China)	758	798	839	844

2) Non-consolidated Personnel Information

(persons)

March 31	2006	2007	2008	2008
				Sep 30
Total employees	3,906	4,050	4,137	4,352
Production	817	819	800	814
Research and development	1,032	1,101	1,123	1,176
Sales, marketing and administration	2,057	2,130	2,214	2,362
Total personnel cost (billions of yen)	64.0	60.9	57.9	30.2

^{*} The number of total employees shown in the above represents all personnel working at Eisai group/Eisai Co., Ltd., including

11. Major R&D Pipeline Candidates

1) By Development Stages

(1)New Approval

	Product Name Research Code	Indication/Mode of Action or Category	Region	Approved	Form.
	HUMIRA	Rheumatoid arthritis/human anti TNF- α monoclonal antibody	Japan	April 2008	lnj.
	(D2E7) IOMERON (E7337)	Additional dosage & formulation: for use in dynamic computed tomography of the liver	Japan	May 2008	lnj.
	ACIPHEX (E3810)	Additional indication: short-term treatment of gastroesophageal reflux disease (GERD) in adolescents	US	June 2008	Oral
#	ALOXI (E3270)	Additional formulation: oral formulation for the prevention of acute chemotherapy-induced nausea and vomiting (CINV)	US	August 2008	Oral
#	GASMOTIN	Gastroprokinetic agent (generic name: mosapride citrate)		September 2008	Oral

(2)Under Review/Preparing for Submission

١-	_,				
	Product Name Research Code	Indication/Mode of Action or Category	Region	Submission /Target	Form.
	ARICEPT	Additional indication: vascular dementia	US	November 2002	Oral
	(E2020)		(EU)	(In preparation)	
	T-614	Rheumatoid arthritis (generic name: iguratimod	Japan		Oral
	ARICEPT	Additional formulation: liquid formulation	ΕU	May 2004	Oral
	(E2020)				
	rufinamide	Anti-epileptic agent (generic name: rufinamide)	US	January 2006	Oral
	(E2080)				
	E2014	Cervical dystonia (generic name: botulinum toxin type B)	Japan	December 2006	lnj.

(3)Clinical (Phase III-II/III)

Product Name Research Code	Indication/Mode of Action or Category	Region	Phase	Submission Target	For
E5564	Severe sepsis/endotoxin antagonist	US		FY2009	lnj
	(generic name: eritoran)	EU			
		Japan			
E7389	Anticancer agent (breast cancer)/microtubule	US		FY2009	In
	dynamics inhibitor (generic name: eribulin)	EU			
	(3)	Japan			
AS-3201	Diabetic complications/aldose reductase	US		FY2012	Or
7.0 020.	inhibitor (generic name: ranirestat)				٠.
ARICEPT	Additional formulation and dosage:	US		FY2009	Or
(E2020)	sustained release formulation	EU		1 12000	O.
ARICEPT		US		FY2009	Or
_	Pediatric usage	US		F12009	Oi
(E2020)	(cognitive impairment due to chemotherapy)	110		EV0000	
ARICEPT	Pediatric usage (Down's syndrome)	US	III	FY2009	Or
(E2020)	A 180			-	
ACIPHEX	Additional formulation: long-acting formulation	US		FY2009	Oı
(E3810)					
SAFORIS	Oral mucositis/glutamine oral suspension	US			Oı
(E6014)					Sus
ZONEGRAN	Additional indication: monotherapy for epilepsy	EU		FY2010	Oı
(E2090)					
ZONEGRAN	Additional indication: pediatric epilepsy	EU		FY2009	Oı
(E2090)					
DACOGEN	Additional indication: efficacy in survival benefit in	US			In
(E7373)	myelodysplastic syndrome (MDS)				
DACOGEN	Additional indication: acute myeloid leukemia (AML)	US		FY2010	Ir
(E7373)	,				
HUMIRA	Additional Indication: juvenile rheumatoid arthritis	Japan		FY2011	In
(D2E7)					
HUMIRA	Additional Indication: ankylosing spondylitis	Japan			Ir
(D2E7)	, . ,				
E2007	Anti-epileptic agent/AMPA receptor antagonist	US	III	FY2012	Oı
	(generic name: perampanel)	EU	III		
SEP-190	Insomnia/GABA _A receptor agonist	Japan		FY2010	Oı
	(generic name: eszopiclone)	- 200.1			٠.
clevudine	anti-chronic hepatitis B agent	China	preparing		Oı
	(generic name: clevudine)	-	for III		
E0302	Amyotrophic Lateral Sclerosis (ALS)	Japan	/		Ir
	(generic name: mecobalamine)	•			
HUMIRA	Additional Indication: Crohn's disease	Japan	/	FY2009	In
(D2E7)		•			
amolimogene	Cervical dysplasia/therapeutic DNA vaccine	US	/	FY2011	Ir
(E7101)					
PARIET	Additional dosage: Reflux esophagitis	Japan	/		O
(E3810)	· -				

^{#:} updates from July 2008

NOTE: development of ZONEGRAN was determined to focus on monotherapy in epilepsy and adjunctive therapy in pediatric epilepsy. Accordingly, the development for generalized seizures adjunctive therapy in Europe (Phase III) has been terminated.

(4)Clinical (Phase II)

Product Name Research Code

Indication/Mode of Action or Category

Region

Phase

2)By Therapeutic Areas

(1)Neurology

Product Name Research Code	Description	Development Status	Origin
ARICEPT (E2020)	Currently approved acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.	Additional Indications Vascular dementia: under review (US) Pediatric usage: Phase III (US) Lewy body dementia: Phase II (Japan) Additional formulations Liquid: under review (EU) Jelly: under review (Japan) Sustained-release formulation: Phase III (EU/US)	in-house
E2007	The generic name is perampanel. It could potentially be developed for treating a variety of neurodegenerative disorders by selectively antagonizing the AMPA-type glutamate receptor.	Epilepsy: Phase III (EU/US) Neuropathic pain: Phase II (EU/US) Migraine prophylaxis: Phase II (US) Multiple sclerosis: Phase II (EU)	in-house
AS-3201	The generic name is ranirestat. It is being investigated as a potential treatment for diabetic complications through inhibition of aldose reductase.	Diabetic neuropathy: Phase III (US)	Dainippon Sumitomo Pharma
rufinamide (E2080)	The agent has been approved in Europe for adjunctive therapy for Lennox-Gastaut syndrome (LGS) under the brand name of INOVELON. (The brand name in the US has not been decided.)	Adjunctive therapy in LGS and partial- onset seizures (in adult): under review (US)	Novartis
ZONEGRAN (E2090)	The generic name is zonisamide. It is believed to have broad anti-epileptic action and to be well-tolerated. Currently indicated as adjunctive therapy for partial seizures in adults with epilepsy.	Additional indications Monotherapy: Phase III (EU) Pediatric indication: Phase III (EU)	Dainippon Sumitomo Pharma
E0302	Mecobalamine is widely used for the treatment of peripheral neuropathy in Japan. A Phase II/III study for amyotrophic lateral sclerosis (ALS) is ongoing.	Amyotrophic lateral sclerosis: Phase II/III (Japan)	in-house
E2014	Botulinum toxin acts on cholinergic nerve ending synapses and inhibits the release of acetylcholine to relax muscles.	Cervical dystonia: under review (Japan)	Solstice Neuro- sciences
SEP-190	Eszopiclone is a non-benzodiazepine type allosteric $GABA_A$ receptor agonist that may help patients with transient insomnia as well as insomnia in the elderly.	Insomnia: Phase III (Japan)	Sepracor

(2)Oncology and Supportive Care Product Name Research Code

(3) Vascular and Immunological Reaction

Product Name Research Code	Description	Development Status	Origin
HUMIRA (D2E7)	The generic name is adalimumab. It is a human anti-TNF- α monoclonal antibody. In Japan, approval was obtained for the indication of rheumatoid arthritis.	Rheumatoid arthritis: approved (Japan) Additional indication Psoriasis: under review (Japan) Juvenile rheumatoid arthritis: Phase III (Japan) Ankylosing spondylitis: Phase III (Japan)	Abbott
E5564	The generic name is eritoran. The compound has demonstrated endotoxin antagonist activity. It showed expected efficacy and tolerability in a Phase II POC study for severe sepsis, which is caused by endotoxin from various types of gram-negative bacteria.	Severe sepsis: Phase III (Global Development Program)	in-house
E5555	The compound inhibits platelet aggregation and smooth-muscle proliferation based on thrombin receptor antagonistic action.	Acute coronary syndrome: Phase II (Japan/US/EU) Atherothrombotic disease: Phase II (Japan/US/EU)	in-house
E6201	The agent is a novel MEK-1/MEKK-1kinase inhibitor.	Psoriasis: Phase II (US)	in-house
T-614	The agent suppresses inflammatory cytokine production, lymphocyte proliferation and immunoglobulin production.	Rheumatoid arthritis: under review (Japan)	Toyama Chemical

(4)Gastrointestinal Disorders

Product Name Research Code	Description	Development Status	Origin
ACIPHEX/ PARIET (E3810)	The agent is a proton pump inhibitor and is approved for duodenal ulcers, reflux esophagitis and eradication of <i>H. pylori</i> infection, etc. In addition, short-term treatment of GERD in adolescents was approved.	Additional indications Gastro-esophageal reflux disease (GERD) in adolescents: approved (US) Non-erosive GERD: in preparation for resubmission (Japan) Additional dosage Reflux esophagitis: Phase II/III (Japan) Additional formulation Long-acting formulation: Phase III (US)	in-house
GASMOTIN	The generic name is mosapride citrate. It is a selective serotonin 5-HT ₄ receptor agonist that has gastroprokinetic and gastric evacuation effects by enhancing acetylcholine release.	Gastroprokinetic agent: approved (Thailand), under review (Malaysia/Indonesia/the Philippines), prepared for submission (six Asian countries including some ASEAN members)	Dainippon Sumitomo Pharma

(5)Other Therapeutic Areas

Product Name Research Code	Description	Development Status	Origin
IOMERON (E7337)	The agent received approval as a non-ionic X-ray contrast medium in computerized tomography in Japan. Additional dosage & formulation for usage in dynamic computerized tomography of the liver was approved.	Additional indication and formulation Contrast medium in computerized tomography: approved (Japan)	Bracco
KES524	The generic name is sibutramine. It inhibits the reuptake of the cerebral neurotransmitters serotonin and noradrenaline. By enhancing the feeling of satiety and increasing energy consumption, it is expected to promote the loss of body weight.	Obesity management: under review (Japan)	Abbott
clevudine	The compound is a DNA polymerase inhibitor that shows efficacy as an antivirus agent for chronic hepatitis caused by hepatitis B virus.	Chronic hepatitis B: under review (Malaysia/Thailand/Indonesia/the Philippines/India), submission in preparation (three Asian countries including some ASEAN member countries), in preparation for Phase III (China)	Bukwang
GLUFAST	The generic name is mitiglinide. It is an agonist for sulfonylurea receptors in pancreatic beta cells and reduces blood glucose levels by accelerating insulin release.	Diabetes: under review (Malaysia/Thailand/the Philippines/Indonesia), submission in preparation (six ASEAN member countries)	Kissei Pharma- ceuticals
E7210	The compound is a contrast medium for ultrasounds based on the principle of ultrasound reflection by micro bubbles.	Suspended (Japan)	Bracco

12. Major Events

Date	Description
2008 April	Eisai received a notification from the U.S. FDA that it may proceed with the clinical study for E2012,
	a potential next generation Alzheimer's disease treatment <announced 3="" april="" on=""></announced>
	Announced a status of the E2007 (AMPA-type glutamate receptor antagonist) development program
	<announced 11="" april="" on=""></announced>
	HUMIRA, a fully-human monoclonal anti-TNF-α antibody received approval in Japan
	for the treatment of rheumatoid arthritis <announced 16="" april="" on=""></announced>
	European Commission granted orphan drug status to anticancer agents MORAb-003 and MORAb-009
	<announced 16="" april="" on=""></announced>
	Signed an agreement with Sanko Junyaku Co., Ltd., Roche Diagnostics K.K., and Nihon Kohden Corp.
	concerning the sales of COAGUCHEK XS series for simple and quick PT-INR monitoring for
	warfarin-treated patients <announced 17="" april="" on=""></announced>
	Announced a notice of revised business forecast for fiscal year ended March 31, 2008,
	as a result of acquisition of MGI PHARMA, INC. <announced 21="" april="" on=""></announced>
	Introduced CHOCOLA BB ROYAL 2, vitamin B ₂ drink for extreme fatigue in Japan (Launched on May 12)
	<announced 24="" april="" on=""></announced>
May	Gained a favorable ruling by Court of Appeal in the U.K., as the NICE process for developing guidance
	on anti-dementia medicines ruled unfair <announced 1="" may="" on=""></announced>
	Established a new subsidiary for marketing support and maintenance of pharmaceutical machinery in China
	<announced 7="" may="" on=""></announced>
	The U.S. FDA advisory committee voted in favor of approval of fospropofol disodium injection
	<announced 8="" may="" on=""></announced>
	The U.K. Court of Appeal makes decision following ruling with regards to the NICE process on anti-dementi
	medicines <announced 9="" may="" on=""></announced>
	Signed an agreement with Lion Corporation regarding exclusive authorization for sales in Japan
	for an ethical drug of BUFFERIN tablets <announced 12="" may="" on=""></announced>
	Announced the notice on new stock issuance in the form of stock options <announced 14="" may="" on=""></announced>
	Presented 16 papers accepted for ASCO Annual Meeting reporting the latest results from the oncology
	research <announced 16="" may="" on=""></announced>
	Presented a study report of E7389 in heavily pretreated patients with advanced breast cancer in ASCO
	Annual Meeting <announced 16="" may="" on=""></announced>
	Non-ionic contrast media, IOMERON 350 and IOMERON 350 syringe, received approval for use in
	dynamic CT of the liver <announced 22="" may="" on=""></announced>
	Terminated a marketing alliance of BREATHE RIGHT nasal strips with GlaxoSmithKline K.K.
	<announced 29="" may="" on=""></announced>
	Announced a notice with respect to issuance of Unsecured Straight Bonds <announced 29="" may="" on=""></announced>
June	Launched HUMIRA subcutaneous injection 40mg Syringe 0.8mL (fully-human monoclonal anti-TNFα
	antibody) for the treatment of rheumatoid arthritis in Japan. <announced 17="" june="" on=""></announced>
	Announced the transfer of subsidiary stock of Clinical Supply Co., Ltd. <announced 19="" june="" on=""></announced>
	Announced a notice on allocation of stock options (stock acquisition rights) <announced 20="" june="" on=""></announced>
	Clinical sites for MORAb-009 Phase II study was expanded to the European Union (EU)
	A U.S. subsidiary Morphotek, Inc. signed a license agreement with the National Cancer Institute (NCI)
	for the development of therapeutic antibodies for use in the treatment of prostate cancer